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Abstract
Advanced prostate cancer (PrC) is the second leading cause of death from cancer in US
males. Advanced PrC cells are initially androgen-sensitive and thus androgen ablation therapy
causes tumors to undergo regression and fall into a remission phase where residual cells remain
dormant while androgen levels remain very low. Unfortunately, this phase usually lasts 3 to 5
years prior to tumor relapse, where the tumor cells re-grow in the absence of androgens. This
form of the disease is aggressive and invariably fatal.

In this study, we investigated the effects of a combination of herbal extracts on various
stages of PrC, androgen-dependent and castrate-resistant, using CWR22 and CWR22Rv1 cells,
respectively. Zyflamend, a commercially available product consisting of 10 different herbal
extracts, had been shown to reduce pre-malignant forms of PrC in clinical trials. We expanded
these earlier experiments by using Zyflamend in a model of advanced PrC. Our initial results
indicated that Zyflamend could repress androgen-sensitive and castrate-resistant (androgeninsensitive) prostate tumor growth. Using a cell model for castrate-resistant PrC, Zyflamend
inhibited the growth of CWR22Rv1 cells by increasing the expression of the cell cycle inhibitors
p21 and p27. These effects were mediated via hyperacetylation of histone 3 through the
suppression of class I and II histone deacetylases (HDACs) and an induction of CBP/p300
histone acetyl transferase activity. The latter effect was mediated by the upregulation/activation
of Erk-1/-2 and Elk-1. Zyflamend also inhibited androgen receptor expression, its downstream
gene target, prostate specific antigen (PSA), and increased cell death by inducing apoptosis as
indicated by caspase 3 activity and PARP cleavage. The reduction of androgen receptor was
confirmed in CWR22Rv1 xenograft tissues. Our results suggest the extracts of this herbal
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combination inhibits castrate-resistant prostate cancer cell growth epigenetically and by
coordinately affecting androgen receptor signaling pathways involved in cell growth/death.
In an androgen-dependent PrC tumor xenograft model, Zyflamend reduced the growth of
CWR22-derived tumors and enhanced the responsiveness of tumor cells to hormone ablation.
Zyflamend potentiated the regression of PrC cells and their sensitivity to androgen deprivation.
These results suggest that Zyflamend may be an effective adjuvant when used with hormone
ablation therapy.

Keywords: prostate cancer, CWR22, 22Rv1, xenograft model, Zyflamend, HDACs, p21,
androgen receptor
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Chapter I
Prostate Cancer

1

1. Introduction

Prostate cancer is the most commonly diagnosed solid malignancy and in the last few
years the incidence of prostate cancer has risen dramatically and become the second leading
cause of cancer-related deaths in men in the United States and most developed countries (1-3).

Progression of prostate cancer is a long process, and it often needs decades to develop
into a clinically relevant disease. Prostatic intraepithelial neoplasia (PIN) is characterized by
increased cellular irregularity and abnormal tissue morphology. Development of PIN takes
~twenty years, with another 10 years to progress to cancer (4). The incidence of prostate cancer
increases dramatically from the fifth decade of life (5.3-14%) to the ninth decade (40-80%). The
disease is diagnosed by monitoring the blood levels of prostate specific antigen (PSA) and with a
tissue biopsy (5). At the early stages, the tumor is considered “low-grade” (Gleason grade 1-3).
After three to fifteen years, early stages of the disease will progress to more advanced forms
(Gleason grade 4-5) (6), eventually metastasizing to secondary sites, such as bone.

Metastatic prostate cancer can be defined by four phases. The first phase is androgendependent growth. In this stage, cancer cells are sensitive to the male hormone known as
androgen and therapy often involves the removal of testosterone. Hormone ablation therapy by
blocking the androgens/ androgen receptor activation leads to the regression of tumor. The
second phase is characterized by regression following hormone deprivation. Following
regression, the disease is considered to be in remission and this stabilization phase (Phase III)
typically last between 3-5 years. During this time, blood PSA, a protein produced by prostate
epithelial cells, is regularly measured to monitor the disease progression. The fourth phase is the
androgen-independent phase. Tumor cells inevitably progress (relapse) in the absence of
2

androgens. The relapsed tumor is remarkably aggressive and death occurs within one to two
years (Figure 1.1).

Epidemiologic studies suggest that multiple factors, including high fat diet, family history,
age and high serum androgens, affect the incidence of prostatic cancer and its mortality (7, 2, 8).
In this study, we are interested in the effects of dietary compounds on the advanced prostate
cancer progression by blocking cell proliferation using androgen-dependent and androgenindependent prostate cancer cell lines. The dietary compounds used in this study are a mixture of
herbal extracts, Zyflamend®; some of the herbal extracts have been shown to have anti-cancer
properties in vitro and in vivo studies (9-15). Therefore, a combination of these herbal extracts
might have a universal effect on inhibiting cancer cell growth through multiple pathways.

Figure 1.1 The Natural History of Advanced Prostate Cancer Cells Following HAT
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1.1 Actions of androgen

In the eighteenth century, John Hunter was the first to reveal testicular function, and one
hundred years later, Arnold Bechter reported the relationship between the behavior and
physiological castration to a substance secreted by the testis into the plasma. In 1889, Charles
Edouard Brown-Séquard isolated the extract derived from dog and guinea pig testis. Forty-five
years later, Leopold Ruzicka and colleagues isolated the testicular hormone and named it
testosterone. One year later, testosterone was artificially synthesized by Butenandt and Hanish
(16). Nowadays, testosterone is one of many compounds in a group of male steroid hormones
called androgens, including androstenedione, dehydroepiandrosterone and testosterone.

Androgens are important steroid hormones in males playing many physiological roles,
including differentiation and maturation of the male sexual organs and contributing to male
secondary sex characteristics (17). Androstenedione is produced in the adrenal glands and
converted into testosterone in testis Leydig cells and peripheral tissue and it can be metabolized
to estradiol by the action of aromatase. Dehydroepiandrosterone is produced in the adrenal
cortexand is also synthesized de novo in brain (18). It is metabolized to androstenedione and
androstenediol prior to their conversion to testosterone. Testosterone biosynthesis in testicular
Leydig cells declines with age and these changes are related to increased expression of
cyclooxygenase-2 and the decrease expression of steroidogenic acute regulatory protein (19)
(20). The production of testosterone is regulated by feedback of luteinizing hormone (LH) and
luteinizing hormone-releasing hormone (LHRH) of the gonad-hypothalamus-pituitary axis.
Testosterone, the major circulating androgen in humans, diffuses into cells and is converted to
5α-dihydrotestosterone by 5α-reductase. In the cytoplasm, 5α-dihydrotestosterone binds to the
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androgen receptor (AR) or a nuclear receptor (estrogen receptor) and further binds to hormone
responsive elements such as androgen responsive elements and/or estrogen responsive elements
to activate related gene transcription and stimulation of insulin growth factor- I (IGF-I)
expression (21), and stimulating proliferation of prostate cancer epithelial cells (17).

In addition to androgen receptor, it is found that testosterone binding to a sexual hormone
binding globulin (SHBG) or an androgen binding proteins (ABP) (22). A complex of testosterone
and binding proteins bind to membrane testosterone binding sites and this association initiates a
rapid action (seconds~minutes) involving endocytosis (23), and the actin cytoskeleton, ionchannels (TRPM8 (24)) and transporters affecting intracellular Ca2+ fluxes (25). This rapid
association recruits heterotrimeric guanine nucleotide-binding proteins (G-proteins) and
stimulates the downstreat signal transduction including PI3K, Ras and Src pathways (26-27).

In summary, the action of androgen signaling can be divided into two groups, direct
steroid action, and indirect steroid action, described as the “Mannheim classification” (28). In the
direct steroid action, membrane vesicles, fluidity and permeability as well as rapid responses
would be changed without cell membrane receptors. In the indirect steroid action, the action of
the steroids, requiring steroid receptors such as intracellular androgen receptors and SHBG
receptors, mediate the activation of cAMP/PKA and induce AR and AR-related genes expression
such as prostatic specific antigen (PSA) (29), and enhance phosphorylation of AR (30-31) and
activation of Ras/Raf-1/Erk (32) and Ras/PI3K (33).

Whether androgen functions through an intracellular receptor (AR)-mediated pathway or
through a rapid response-signal transduction pathway, they promote prostate cancer cell
proliferation and tumorigenesis.
5

1.2 Hormone ablation therapy in androgen-dependent advanced prostate cancer

Androgen-dependent prostate cancer cells require the presence of androgens for growth.
In 1941, Huggins and Hodges observed that malignant tumors arising from the prostate gland
were partially responsive to the withdrawal of androgens and this led to the hormonal
management of prostate cancer. This finding provided the solid basis for advanced prostate
cancer treatment (34). Androgen deprivation therapy (ADT) is considered one of the first-line of
treatments for men with high-grade, clinically localized prostate cancer who undergo
radiotherapy (35) or metastatic prostate cancer (36). There are various methods to achieve
testosterone ablation. Primary hormone ablation therapy includes maximal androgen deprivation
(MAD) (also known as maximal androgen blockage, MAB). Maximal androgen deprivation
refers to a combination of androgen suppression (AS) and anti-androgen therapy using
luteinizing hormone-releasing hormone (LHRH) agonists to achieve medical castration and nonsteroidal anti-androgens, such as flutamide, to inhibit tumor growth and increase 5-year survival
rates (37).

Following primary therapy, the patients are monitored by measuring PSA levels as an
indicator of tumor growth. If chemical relapse should occur (increasing PSA levels), patients
could receive secondary hormone therapy. Secondary hormone ablation therapy 1) inhibits the
production of adrenal androgens using corticosteroids, ketoconazole or liarozole and
aminoglutethimide; 2) involves androgen receptor blockade using steroidal anti-androgens, such
as cyproterone acetate, or non-steroidal anti-androgens, such as flutamide; 3) or involves
estrogen therapy, using transdermal estradiol (38). Castrate-resistant prostate cancer (CRPC) is
resistant to these therapies (39-41). Ultimately, men will develop a disease that is androgen-
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independent /hormone refractory and eventually fatal.

1.3 Androgen-independent prostate cancer

Approximately 90% of advanced prostate cancer patients response to hormone
ablation therapy (HAT); however, most still suffer tumor relapse within 5 years (42-43).
Relapsed tumor cells can survive in the absence of androgens resulting in tumors that are
unresponsive to treatment with an invariably fatal outcome. The mechanism of resistance to
androgen withdrawal is being investigated. One of the mechanisms targets androgen
signaling. During androgen deprivation, the loss of androgen appears to be a form of stress
that may transform cells to derive from androgen-dependence to androgen-independent
growth (44). There are several pathways leading to androgen-independent prostate cancer
(in the absence of androgens). These pathways have been reviewed by Pienta KJ et al. (45)
and Feldman BJ et al (46) and are summarized below.

1.3.1 The hypersensitive pathway

To survive in an environment of low levels of androgens, prostate cancer cells develop
castration-resistance, as opposed to androgen independence, by increasing expression and
sensitivity of androgen receptors, and by increasing 5α-reductase activity (47-48) to compensate
for the low levels of androgens. Following hormone ablation therapy, 30% of recurrent prostate
cancers have amplified androgen receptor gene expression with no amplification in primary
tumor (49). In addition to an induction of androgen receptor, androgen receptor sensitivity is
increased (lowering threshold) along with an increase in receptor stability (50), increasing the
importance of local androgen production. After hormone ablation therapy, serum testosterone
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levels decrease by 90%, but the level in prostate tissue is only reduced by 60% in compensation
for the decline of testosterone in the circulation (47). The genes involved in steroid biosynthesis,
such as HMG-CoA synthase, squalene synthetase, squalene mono-oxygenase, and lanosterol
synthase have been found to be increased in recurrent human prostate carcinoma (51).

1.3.2 The promiscuous pathway

Most of the prostate cancer cells that are androgen-independent have been found to
express androgen receptor. Some of prostate tumor cells develop amplified androgen signaling
by increasing androgen receptor expression, androgen receptor sensitivity and local androgen
production; other prostate tumor cells develop mutations on androgen receptors associated with
alterations of co-regulators (52-53). Forty-four mutations of the androgen receptor have been
identified, and twenty of those mutations had gain of function. Five of the twenty gain of
function mutants had promiscuous activity that enhanced the activation of androgen receptor by
non-androgenic steroid and anti-androgen molecules (52). The enhancement of androgen
receptor promiscuous pathways can also be achieved through an induction of co-regulators such
as cAMP response element-binding protein (CREB)-binding protein (CBP). The increasing
androgen receptor activity and co-regulators promotes cancer cell survival against anti-androgen
molecules (54).

1.3.3 The outlaw pathway

Androgen receptor signaling can be activated by outlaw receptors in a ligand-independent
mechanism. IGF-1/IGF-1R has been shown to activate androgen receptor in the absence of
androgen and induce prostate-specific antigen (PSA) expression (55). On the other hand, some
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mutant androgen receptors are unable to bind DNA but can potentiate membrane tyrosine kinase
signaling, such as activation of the Src-Erk1/2 pathway and induction of IGF-1R expression (56).
Epidermal growth factor (EGF) has been found to activate the androgen receptor (55) and
cytokines, including IL-6, has been shown to induce androgen synthesis (57).

1.4 The animal models of prostate cancer research

The development of prostate cancer takes many decades and the disease is very diverse in
humans. This is a limitation in studying prostate cancer.. Therefore, identifying a suitable animal
model would be a helpful tool to study this disease. The development of animal models of
prostate cancer is important for the investigation of improved therapeutic strategies and to
identify underlying molecular mechanisms in the event of effective intervention. Over the last 30
years, many rodent models have been developed, mimicking different physiological stages of
prostate cancer progression. There are rodent models that study the disease as it forms
spontaneously, or where prostate cancer is induced and xenograft models where human prostate
cancer cells are grown subcutaneously in immune-compromised mice. Other models study premalignant forms of the disease (prostatic intraepithelial neoplasia, PIN), carcinomas, and
metastasized tumors, in addition to models that are sensitive and insensitive to androgens (Table
1.1). These models show that 1) androgens are necessary for most prostatic carcinomas, 2) most
advanced prostatic carcinomas eventually develop androgen-independence, and 3) advanced
prostatic carcinomas metastasize to regional lymph nodes or distant organs such as bones and
liver (58). However, it should be recognized that no single model can represent the diversity of
the disease.
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1.4.1 Rodent models

There are two major categories of rodent models when studying prostate cancer; one is
the spontaneous rodent model and the other is the induced rodent model. Of the spontaneous
rodent models, the Dunning rat model (59) is the most common and widely used model in
nutritional studies (60). This model has identified some critical genes importatnt in the prostate,
such as CD44. The Dunning R-3337 is derived from Dunning rat model and develops well
differentiated adenocarcinomas. Sublines of Dunning R-3337 have a variety of characteristics of
the disease being either highly metastatic or involving AR deficiency (61). ACI/Seg and LobundWister rat models have also been used for nutritional studies for the progression of the disease.
ACI/Seg rat model has a long lifespan with an age-related incidence of cancer, but the tumor
does not metastasize. The Lobund-Wister rat model develops prostate adenocarcinomas that
metastasize to the lung. This model has androgen-dependent properties in early stages of the
disease but becomes androgen-independent thereaftere. In a N-methyl-N-nitrosourea
(MNU)/testosterone propionate (TP) system, prostate adenocarcinomas can be induced by MNU,
followed by a promotion with TP (62). Fisher F334 and Noble rats are rodent models whose
prostate tumors are induced by carcinogens. The tumors formed in these two models are
androgen dependent and non-invasive.

On the other hand, transgenic mouse models have the advantage of studying the effects of
targeted genes on initiation, promotion, and progression of prostate cancer, providing a useful
tool for therapeutics. For example, the TRAMP (transgenic adenocarcinoma mouse prostate)
model has been used to study of the effects of post castration, oncogenes, and the role of IGF
axis (63). TRAMP mice contain a rat probasin (PB), a nuclear protein expressed in the epithelial
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cells of the rat prostate. PB is regulated by androgens, showing a similar PSA expression pattern
as that of humans. The TRAMP model has a high incidence for the development of prostatic
adenocarcinomas, with no metastasis. To study the progression from low grade PIN to high grade
PIN, and development to invasive adenocarcinoma, C3(1)/SV40 transgenic mouse model
containing a well characterized androgen-driven prostatic steroid binding protein (PSBP). This
C3(1)/SV40 transgenic mouse model supports the idea that PIN is a precursor of carcinomas of
the prostate (63).

Knockout mouse models provide an advantage when studying targeted gene alterations
on prostate cancer progression. In patients with early stages of prostate cancer, deletions of Pten
and Nkx3.1 have been identified (64-65) and thus a heterozygous of Pten and Nkx3.1 double
mutation mouse model has been established. Nkx3.1+/-/Pten+/- mice develop invasive
adenocarcinomas accompanied by metastasis to lymph nodes after one year. After treatment of
high-grade PIN with androgen ablation in these the mice, the prostate cancer cells exhibit
androgen-independent properties (66-67) mimicking relapsed patients on hormone ablation
therapy.

1.4.2 Xenograft model

The above models are based on rodent prostatic tumor cells, not human prostatic tumor
cells. In order to study human prostate cancer in rodent models, athymic nude mouse xenograft
models have been developed using cell lines derived from human prostate cancer. These human
cells are derived from the tumors of prostate cancer patients and are transplanted into immunedeficient mice. A xenograph model using androgen-sensitive PC-82 cells (established in 1977)
was the first prostate cancer xenograft model developed. Soon after, two androgen-independent
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cell lines, PC-133 and PC-135, were established. (68). Since then, there are more than 25
xenograft models of human prostate cancer (61). In 1993, Pretlow‟s group from Case Western
Reserve reported the initial use of the CWR22 prostate cancer cell line (69). This human cell line
was derived from a primary tumor and is highly androgen dependent. When grown in a
xenograph model, tumor regression occurs following androgen deprivation. Relapses to an
androgen-independent line, CWR22R occurs in 30-50% of the animals within 3-10 months of
castration (69). Microarray analysis has been identified changes (cutoff >2.5 fold) between
CWR22-derived androgen-dependent tumors, and the CWR22R-derived androgen-independent
tumors. Thirteen genes that increased were associated with thyroid hormone receptor signaling
and cell surface receptors; 44 genes were decreased (70). In addition, mutations of hAR signaling
of the CWR22 cell line has been reported with a mutation in the ligand-binding domain of the
hAR gene which can be transcriptionally activated by testosterone, dihydroxytestosterone (DHT),
dehydroepiandrosterone (DHEA), estradiol, progesterone, and the anti-androgen
hydroxylflutamide (71). This AR mutation is found in relapsed prostate cancer patients, and in
the CWR cell line series of androgen-independent xenograft models (CWR22, CWR22R, and
CWR91). As such, these models have been used for the evaluation of drug therapy (72).

Other xenograft models can be generated using various cell lines, such as androgendependent LNCaP cell line and androgen-independent PC3 and DU145 cell lines. These models
are widely used to study the androgen dependent and androgen-independent stages of prostate
cancer. The properties of these cells are discussed in the next section.
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Table 1.1 Rodent models of prostate cancer (66-67, 59, 73-74, 60, 58, 62, 61, 63, 68)

Model

PIN/CaP
Metastasis Androgen
pogression
status
Spontaneous rodent model
ACI/Seg rat
Lobund-Wister
(Pollard) rat

>33 mo
>26 mo

No
lung

Dunning rat

2 mo

lung

Induced rodent model
Lobund-Wister
10.5 mo
(Pollard) rat

Fisher F334 rat

20 wk

Noble

44 wk

Wistar rat

2 mo

Features of cancer

30-40% develop to invasive
ND
adenocarcinoma
AD in early High grade PIN
stage; then
AID
AID
rapid growth and rapid
metastasis

lung, liver

AD in early three types of cancer develop:
stage; then moderately to poor
AID
differentiated prostatic
adenocarcinoma,
hepatocellular carcinoma, and
lung carcinoma
No
AD when
moderately differentiated
DMAB
noninvasive cancer
followed
by TP; AID
when
DMAB+TP
rare
AD
100% of rats develop PIN and
then CaP by testosterone
treatment for 16 wk and for 44
wk, respectively
lymph
AD
10% incidence of metastasis in
node, lung,
one yr
rare to
bone

ND: no determined; NE: neuroendocrine; AD: AR dependent; AID: AR independent; WT:
wild type; DMAB: dimethylbenz(a)anthracene; TP: testosterone propionate
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Table 1.1 Continued.

Model

PIN/CaP
Metastasis Androgen
pogression
status
Transgenic mouse model
Probasin- SV40 T
7-12 wk
lymph
variable
antigen (TRAMP)
node, lung,
kidney,
bone,
adrenals
(28 wk)
Large probasin-SV40 10-22 wk No
AD
T antigen
Fetal Gγ globin
16-20 wk lymph
AID
node, lung,
kidney,
bone,
thymus,
adrenals
(24 wk)
C3(1)-SV40 T
8-28 wk
rare
ND
antigen
C3(1)-polyomavirus
11 wk
No
ND
middle T
Cryptdin-SV40 T
8-12 wk
lymph
AID
antigen
node, liver,
lung, bone
(24 wk)
Pten, Nkx3.1 mutant
6 mo
lymph
AID
mice
node
lesions
with WT
AR
Xenograft modelOrigin
AD/AI
AR
CaP cell lines
CWR22
prostate
AD
mutant
LAPC-3
prostate
AID
WT
LAPC-9
bone
AD
WT
LuCaP 23.1
lymph
AD
N/A
node
LuCaP 23.12
liver
AD
N/A
MDA Pca-31
liver
N/A
positive
PC-82
prostate
AD
WT
PC-329
prostate
AD
WT
PC-374
skin
AID
WT
14

Features of cancer

progressive disease restricted
to the prostate epithelium;
metastatic adenocarcinomas
are partially androgenindependent
invasive adenocarcinoma
progressive prostate disease
with epithelial and NE feature

invasive adenocarcinoma
invasive adenocarcinomas
NE-derived progressive
prostate disease

HGPIN/early carcinoma
lesions

PSA
positive
positive
positive
positive
positive
positive
positive
positive
positive

1.5 The cell model of prostate cancer research

To study the underlining mechanisms of prostate cancer progression, cell models have
been developed that mimic various stages of prostate epithelial cells, normal and neoplastic,
including those cells that are androgen-dependent and androgen-independent (Table 1.2).
Different cell lines are thought to represent different characteristics of the disease. For example,
a mutation of the androgen receptor has been found in LNCaP cells and this mutation results in
the substitution of alanine for threonine at position 877 (T877A) (75). The same mutation was
observed in metastatic tumor tissues from six out of twenty-four patients (76) and was also
observed in bone marrow metastatic tissues from 5 out of sixteen patients receiving combined
androgen blockage and flutamide (77), indicating this mutant form of the androgen receptor is
common in patients. Therefore, LNCaP cells can potentialy become androgen independent. The
use of LNCaP cells to mimic the transition of androgen dependence to androgen independence
has been widely used to study the signaling mechanisms and genotypes during prostate cancer
progression after androgen deprivation.

MDA PCa 2b is an androgen dependent cell line that was derived from a tumor that
metastasized to bone. MDA PCa 2b cells have an androgen receptor mutation (T887A and
L701H) and this mutation reduces the binding affinity of androgen. Although MDA PCa 2b cells
are less sensitive to androgens, they can still respond to androgens and produce PSA (78).

Similarly, androgen receptor mutation was also found in CWR22 cells at position 874
(substitution of tyrosine for histidine) in the ligand binding domain at c-terminus. This mutation
influences the binding of co-regulators and its transcriptional activity (79).
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PC3 and DU145 cells are the most common cell lines used to study the mechanisms of
androgen-independent cell/tumor growth. However, these two cell lines do not express an
androgen receptor and do not produce PSA, two key components associated with advanced and
metastatic prostate cancer. It is believed that expression/activation of androgen receptor plays an
important role in the resistance to hormone ablation therapy and contributes to the transformation
of androgen-dependent to androgen-independent cell growth. Therefore, the use of these two cell
lines are unable to address the role of the androgen receptor in the disease.

CWR22Rv1 cells are derived from relapsed CWR22 cells and are castrate-resistant cells.
CW22Rv1 cells can survive in the absence of androgen but can still respond to androgen
stimulation. Androgen receptor is expressed by CWR22Rv1 cells and PSA is produced in the
presence of androgen. CWR22Rv1 cells express two isoforms of androgen receptor; one is a
114-kDa protein and other one is a 75~80-kDa protein. The two isoforms have been identified.
The 114-kDa protein has a duplication of exon 3 encoding zinc finger domain of the androgen
receptor DNA-binding site, while the truncated protein lacks the ligand-binding domain (LBD)
in COOH-terminus, referred to as ARΔLBD (80), these two isoforms do not exist in parental
CWR22 cells. The in-frame androgen receptor regulates endogenous androgen-dependent gene
expression and the truncated androgen receptor promotes cell proliferation in a ligandindependent manner. The two isoforms of androgen receptor is constitutively expressed and are
active following hormone deprivation. Because of these characteristics of androgen receptors
expressed in CWR22Rv1 cells, CWR22Rv1 cells have advantages when studying the
progression of prostate cancer during the refractory state and can serve as a model to understand
the mechanism of transition from androgen-dependent to androgen-independent cell growth. As
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such, CWR22Rv1 cells were the cell model of choice for the in vitro and in vivo studies in this
project.
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Table 1.2 Cell models of human prostate cells

human

ATCC#

disease

tumori
genic

source

AR

AD/
AID

PSA

cell line
immortalized prostate cells
RWPE-1
CRL-11609
RWPE-2
CRL-11610
PWR-1E
CRL-11611
PZ-HPV-7
CRL-2221
WPE1-NA22
CRL-2849
WPE1-NB14
CRL-2850
WPE1-NB11
CRL-2851
WPE1-NB26
CRL-2852
RWPE2-W99
CRL-2853
WPMY-1
CRL-2854
WPE-stem
CRL-2887
WPE-int
CRL-2888
WPE1-NB26-64 CRL-2889
WPE1-NB26-65 CRL-2890
prostate cancer cells
LNCaP
CRL-1740

normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal

No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes

epithelial
epithelial
epithelial
epithelial
epithelial
epithelial
epithelial
epithelial
epithelial
stroma
peripheral zone
peripheral zone
peripheral zone
peripheral zone

+
+
+
+
+
+
+
+
+
+
+
+
+
+

AD
AD
AD
AID
AD
AD
AD
AD
AD
AD
AID
AD
AD
AD

+
+
+
+
+
+
+
+
+
+
+
+
+

carcinoma

Yes

+

AD

+

CA-HPV-10
MDA PCa 2b
VCaP

CRL-2220
CRL-2422
CRL-2876

adenocarcinoma
adenocarcinoma
cancer

No
Yes
Yes

+
+
+

AD
AD
AD

+
+
+

NCI-H660

CRL-5813

small cell carcinoma

left
supraclavicular
lymph node
epithelial
bone
vertebral
metastasis
lymph node

AN
PR

AID

N/A

PC-3
DU-145
22Rv1

CRL-1435
HTB-81
CRL-2505

adenocarcinoma
carcinoma
carcinoma

bone
brain
epithelial

+

AID
AID
AID

+

Yes
Yes
Yes

AD: AR dependent; AID: AR independent; ANPR: atrial natriuretic peptide receptor
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1.6 Cellular mechanisms of prostate cancer

The progression of prostate cancer is a long process and the mechanism is complicated.
The mechanisms involved in tumorigenesis include promotion of cell growth, metastasis and
angiogenesis, as well as inhibition of cell death. The regulation of proliferative mechanisms is
influenced by the surrounding environment, such as factors in circulation, i.e., cytokines and
growth factors, such as IGF-1 and androgens, and the influence of nearby tissues, i.e. fibroblast,
and other stimuli, i.e. hypoxia. These mechanisms are discussed as below.

1.6.1 Cell growth

Cancer progression is associated with the deregulation of cell growth and cell death.
In cancer cells, the signal transduction of cell proliferation is up-regulated. For example,
cell cycle promoting regulators such as cyclin dependent kinases (CDKs) are i nduced and
cell cycle suppressors such as the retinoblastoma (Rb) family and p53 are inhibited, thereby
continuing cell division. In addition, cell death signal pathways are inhibited and thus
cancer cells escape apoptosis, and the growth of cancer cells is promoted. To support tumor
cell growth, formation of new blood vessels provide sufficient nutrients and oxygen for
survival and channel cells from local areas to more distance sites, i.e. bone, in most prostate
cancer patients (81).

1.6.1.1 Cell cycle arrest

Cell growth and division is tightly regulated by cell cycle progression. Cell cycle
stages are defined as Gap 0 (G0), Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M)
phases. In the G0 phase, a resting and quiescent phase, progression through cell cycle and
19

cell division is halted and for transition to the G1 phase. In the G1 phase, the cell is enlarged
and the production of mRNA and protein is increased in preparation for DNA synthesis.
There is an important cell cycle mechanism regulated during this period which is G1
checkpoint. G1 checkpoint, a point of transition of the G1 and S phases, decides whether the
cell continues to the S phase or remains resting in the G0 phase. In tumor cell progression,
the G1 checkpoint is a critical regulatory stage. G1 checkpoint is negatively regulated by
cyclin dependent kinase inhibitors (CDKIs) including Cip/Waf family (p21, p27 and p57)
and INK4 family (p15, p16, p18, p19) and by tumor suppressor genes such as retinoblastoma
(Rb) and p53. Members of the Cip/Waf family bind cyclin/cyclin dependent kinase
complexes and disrupt the catalytic activity of CDKs (CDK4/6 and CDK2) on cyclins
(cyclin D and cyclin E). Disruption of CDKs inhibits DNA polymerase, thymidine kinase
and hydrofolate reductase, all required for DNA synthesis in the S phase. The Rb family is
another major regulator of the G1 phase through the Rb/E2F pathway. E2F is a transcription
factor that binds the promoter region of many genes, such as DNA polymerase subunits, cyclin A
and cyclin E, allowing the initiation of DNA synthesis and progression to the S phase. E2F is
inhibited by Rb to form a Rb/E2F complex in the cytosol; however, E2F is released from the
complex when Rb becomes hyper-phosphorylated by the cdk–cyclin complex (82). In prostate
cancer patients, most of the CDKIs, p21, p27 and p16 and Rb, are repressed by genetic and
epigenetic regulation (83).

The second checkpoint of the cell cycle is at S phase where the cells replicate DNA.
The S phase checkpoint is regulated through ataxia telangiectasia mutated (ATM)/ATM and
Rad3-related (ATR)-checkpoint1 (chk1)-cell-division-cycle 5A (cdc25A) (ATM/ATR-chk1cdc25A) and ATM-Nijmegen breakage syndrome1 (Nbs1) - Structural maintenance of
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chromosomes protein 1 (SMC1) (ATM-Nbs1-SMC1) pathways. DNA damage stimulates
phosphorylation of Ser/Thr kinases, checkpoint kinases 1 and 2 (chk1 and chk2), by ATM or
ATR. Activated chk1/2 phosphorylates the serine sites of cdc25A phosphatase, the inactive
form, thereby reducing the activity of cyclin E and Cdk2. The inactive cyclin E/Cdk2 is
incapable of phosphorylating Cdc45, disrupting DNA replication (84). ATM-Nbs1-SMC1
also regulates the S phase checkpoint. This pathway is induced by ionizing radiation. ATM
phosphorylates SMC1 at S957 and S966 sites, which recruits a phosphorylated Nbs1 as an
adaptor (85). The ATM-Nbs1-SMC1 pathway is distinct from the ATM/ATR-chk1-cdc25A
branch, but it is still required for the activation of the S phase checkpoint.

The third checkpoint is G2/M checkpoint initiating the DNA repair before entering
into the mitosis. Activation of the G2/M checkpoint is induced by ATM/ATR-chk1-cdc25A.
cdc25A phosphatase is inactivated by chk1/2 and binding to 14-3-3 proteins. The 14-33/cdc25A complex translocates into the cytoplasm followed by degradation. Therefore, the
downstream complex, cdk1/cyclin B1, cannot be activated and the structure of chromosome
remains tight, arresting the cell cycle (86).

Checkpoints deregulate cell cycle progression and allow unlimited cell proliferation.
Most cancer treatments focus on enhancing the function of the checkpoints through
radiation therapy or deprivation of hormones or chemotherapies, thereby inducing DNA
damage and activating ATM/ATR pathways, as well as inducing expression of cell cycle
inhibitors resulting in cell cycle arrest.
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1.6.1.2 Cell apoptosis
Cell apoptosis was termed “programmed cell death” (PCD), which is a form of cell
suicide. The mechanisms of programmed cell death have been identified and include
autophagy, paraptosis, mitotic catastrophe and apoptosis (87). Apoptosis is more specifically
defined as a progress of cell death mediated by caspases through intrinsic and extrinsic
pathways. Apoptosis occurs following the removal of growth factors or growth stimulating
hormones, i.e. fibroblast growth factor or androgens, and the exposure of cytotoxic
chemicals or pro-apoptotic ligands, such as TRAIL (TNF-related apoptosis-inducing ligand),
activating the caspase cascade.

Caspase cascade includes intrinsic or extrinsic pathways (88). The intrinsic pathway,
also called the mitochondrial pathway, and is initiated by intracellular stress, DNA damage.
Double-strand DNA damage stimulates ATM (ataxia-telangiectasia-mutanted) activation and
induces the expression of the tumor suppressor gene p53. p53 is an important negative
regulator of the cell cycle and promotes the expression of pro-apoptotic proteins (e.g. puma,
Bax, apaf-1, FasL and DR5) (89). Puma (p53 upregulated modulator of apoptosis, a member
of pro-apoptotic Bcl-2 family) inhibits the association of anti-apoptotic protein Bcl-2, Bcl-x
and pro-apoptotic protein Bax and Bak. Therefore, free Bax and Bak translocate to the outer
membrane of the mitochondria, enhancing the release of cytochrome c and Smac/DIAB LO
(Second Mitochondria-derived Activator of Caspases/Direct IAP Binding Protein with Low PI)
into the cytoplasm (90). Cytochrome c, Apaf-1 and pro-caspase 9 form an apoptosome, a
complex of proteins formed in the process of apoptoisis. In the apoptosome, pro -caspase 9
becomes active by a conformation change and activates the downstream effectors caspase 3,
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6 and 7 and IAPs (inhibitors of apoptosis). Smac/DIABLO inhibits IAPs through physical
interaction, and therefore negatively affects caspase activity (91). Active effectors (caspase
3, 6 and 9) initiate the death substrates, PARP and Gas2 (92), resulting in apoptosis.

The extrinsic pathway is induced by apoptosis-induced ligands, such as FasL/CD95L
and TRAIL, binding to the pro-apoptotic membrane receptors and decoy receptors. Once
activated, the death domain of the receptor recruits the adapter molecules such, as FADD (Fasassociated death domain) and the initiators, pro-caspases 8 and 10, forming a DISC (deathinducing signaling complex). By proteolytic processing, initiator caspase 8 and 10 is active and
activates caspase 9 following the activation of caspase 3, 6 and 7. Initiator caspase 8 and 10
cleave Bid to form tBid (truncated Bid). tBid associated with Bax and Bak forms a channel on
the mitochondrial outer membrane (MOM) and increases MOM permeabilization, releasing proapoptotic proteins, such as cytochrome c. Intrinsic apoptosis is initiated (90, 93).

1.6.2 Metastasis

Metastasis is a process whereby cancer cells relocate to the secondary sites, such as
lymph nodes, lung or bone. In this process, it is involved in angiogenesis, migration and
invasion. While the tumor mass is increasing, angiogenic molecules are generated by the
tumor cells and stromal cells to stimulate new vessel formation. The tumor cells change
their morphology and secrete proteinases to pass through the surrounding barrier and enter
into the circulation. Eventually, tumor cells spread to the other organs.
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1.6.2.1 Angiogenesis

Angiogenesis is a process of new blood vessel formation. In tumors, new vessel
formation provides a mechanism to supply sufficient nutrients, oxygen and pro tumorigenetic factors to the cancer cells and to remove waste form the cell cluster. In
addition, new vessel formation is critical for tumor metastasis. During tumorigenesis,
angiogenesis occurs in different stages of tumor development, including premalignant
lesions and malignancy, and allows tumor progression, thereby increasing tumor mass. This
process is initiated by angiogenic molecules generated by the cancer cells and also by the
stroma under environmental stimuli, such as hypoxia. Angiogenic molecules include
vascular endothelial factor (VEGF), platelet-derived growth factor (PDFG), placental growth
factor (PlGF), angiopoietin-1 (ANG1) and basic fibroblast growth factor (bFGF). VEGF is
one of the most ubiquitous molecules for angiogenesis and released not only from the cancer
cells, but also by fibroblasts and inflammatory cells such as macrophages. VEGF has an
important role in new vessel formation by promoting the growth of vascular endothelial
cells (ECs) and is also a survival factor for ECs by preventing cell death (94). The
expression of VEGF is upregulated by various growth factors, includin g insulin-like growth
factor-1 (IGF-1), PDGF and bFGF, suggesting that the release of VEGF is coordinately
regulated by local hypoxia and growth factors in the microenvironment (95).

In prostate cancer, VEGF and endoglin (a protein that is involved in vascular
remodeling) expression were detected in 50 radical prostatectomy specimens, categorized by
Gleason score. VEGF correlated significantly with angiolymphatic invasion and Gleason score
(P < 0.05) and endoglin correlated positively with Gleason score, lymph node metastases, tumor
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stage, and preoperative prostate-specific antigen level (P < 0.05). Expressions of VEGF and
endoglin were correlated with shorter survival times (96). In addition, serum levels of VEGF
were significantly higher in the metastatic prostate cancer patients compared to patients with
localized tumors (97). These results indicated that the pro-angiogenic molecule, VEGF, was
associated with prostate cancer cell metastasis and progression.
One of the activators of VEGF is hypoxia-inducible factor 1α (HIF-1α). HIF-1α is a
transcription factor and is induced by hypoxia while the tumor mass is increasing. Under a low
oxygen environment, the repressor of HIF-1α, von Hippel-Lindau (VHL), is released from the
HIF-1α-VLH complex (98), resulting in activation of HIF-1α, allowing it to bind to genes such
as VEGF. Overexpression of HIF-1α was observed in prostate malignancy and non-malignant
prostate tissues compared with the normal prostate (99). This is consistent with elevated
expression of VEGF in prostate cancer and increases in the degree of neovascularization with
tumor stage.

1.6.2.2 Migration and Invasion

The translocation of tumor cells as a result of the formation of new vessels, angiogenesis,
requires the ability to pass through a multilayer barrier composed of pericytes, base membrane,
fibroblast and endothelial cells, and is referred to as migration and invasion. Tumor cells
elongate polarize and stiffen while interacting with the surrounding environment, such as
extracellular matrix (ECM) substrates, i.e., collagen, elastin and fibronectin. Tumor cells,
macrophages and fibroblast can secrete ECM-degrading proteases, including urokinase-type
plasminogen activator (uPA) and the matrix metalloproteinases (MMPs) such as MMP2, MMP7,
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MMP9, and MMP12 (100), resulting in ECM degradation and providing space for cell invasion
into the underlying tissue and migration into the circulation.

Tumor cells in the circulation would be attracted by certain growth factors and move to
the secondary site.This interaction between tumor cells and target tissues are hypothesized as
“seed and soil”. Briefly, “seed and soil” hypothesis was first published in 1889 by English
surgeon Stephen Paget where tumor cells are the seed and the target tissues are the soil. He
analyzed more than 900 autopsy records and found that tumor cells metastasize to specific
organs (101). His observations suggested that sites of metastasis are determined by both the
characteristics of those tumor cells and the microenvironment of the host tissue (102). In prostate
cancer, 90% of patients with hematogeneous metastases develop bone metastasis (81),
suggesting that bone marrow-derived cells (VEGF receptor-1 and -2 positive progenitor cells)
and bone-specific matrix in the tumor microenvironment promotes and attracts metastasis to
bone (103). This interaction between local prostate cancer cells and bone marrow is consistent
with the “seed and soil” hypothesis (104). In addition, several growth factors such as IGF-1
produced by bone marrow cells promote prostate cancer growth and survival through a
stimulation of the IGF-1/IGF-1R survival signal pathway.

1.6.3 IGF AXIS

Insulin-like growth factors (IGFs) are polypeptide growth factors secreted from many
tissues with functional homolgy to insulin. There are two types of IGFs, IGF-I and IGF-II,
sharing 62% homolgy in their amino acid sequence (105) and tightly regulated in the circulation
by insulin-like growth factor binding proteins (IGFBPs). Both IGF-I and IGF-II bind to IGF-I
receptor (IGF-IR), a transmembrane tyrosine kinase receptor. IGF-IR is a tetramer of two
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identical α-subunits and two β-subunits. IGF-IR can resemble the insulin receptor forming a
hemireceptor and binds to IGF-I, but not insulin (106). IGF-I/IGF-IR binding presents a similar
signal transduction pathway as the insulin signaling cascade. Over 99% of the circulating IGFs
are bound to IGFBPs, with a majority forming a complex with IGFBP-3 and the acid-labile
subunit (ALS). The binding of IGF-I to this complex prolongs its half-life in the serum. IGFs
have a greater binding affinity with IGFBPs than IGF-I receptors, therefore regulating bioactivity
of IGF and signaling at the cellular level via affinity competition (107). However, the function of
IGFBP is very controversial. In the CWR22 human prostate cancer xenograft model, it has been
shown that IGFBP-5 was regulated by androgen receptor (AR), whereby the interaction of AR
with IGFBP-5/IGF was associated with tumor growth (108). On the other hand, PSA, an
androgen-related gene, induced IGFBP-5 degradation, enhancing IGF/IGF-IR interaction and
IGF-1R phosphorylation., Activation of the IGF-1R signaling pathway promotes malignancy
progression (109). IGF-IIR, on the other hand, has no tyrosine kinase activity and selectively
binds to IGF-II. This process results in the degradation of IGF-II and controls circulating levels.

1.6.3.1

IGF-IR signal in cell proliferation

IGF-I/IGF-IR signaling also modulates cell cycle regulation. Activation of PI3K/AKT by
IGF-I/IGF-IR signaling phosphorylates p70 S6K and elF-4E. Phospho-elF-4E associates with
ribosome and thus accumulated ribosome becomes a sufficient translational machinery to ensure
the rapid processing of transcripts through the cycle (110). Activation of IGF-I/IGF-IR increases
the release of E2F from retinoblastoma (Rb). It also increases synthesis of cyclin D1, cyclin E
and CDK4 through MAPK (Erk) activation (111) (112), and reduces the expression of the cell
cycle inhibitors p21 and p27 (113). Collectively, these events promote the transition of the cell
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cycle from G1 to S phase. The production of cyclins A and cdc2 are induced by IGF-I/IGF-IR
signaling and thereby enhance cell cycle progression from the G2-M phase (114). Taken together,
IGF-I/IGF-IR activation promotes cell cycle at several phases, mainly through AI3K/AKT and
MAPK pathways, and thereby inducing cell proliferation.

1.6.3.2

IGF-IR signal in apoptosis

Downstream of IGF-I/IGF-IR signaling cascades are AKT and MAPK intracellular
signaling. The IGF-1R activation leads to autophosphorylation on tyrosines 1131, 1135 and 1136
in the kinase domain, followed by phosphorylation of juxtamembrane tyrosines and carboxyterminal serines and subsequent phosphorylation of insulin receptor substrate (IRS) proteins
(115). Signal transduction proceeds through IRS with the activation of PI3K/AKT and MAP
kinases and involves phosphorylation of downstream substrates including the members of Bcl-2
family, Bad and forkhead transcription factors (i.e., FKHRL1), and caspases (107, 116).
Phosphorylated Bad binding to 14-3-3 proteins relocates into cytosol and neutralizes the proapoptotic function of Bad (117-118). In addition, AKT activation inhibits the caspase cascade by
phosphorylation of caspase 9 and caspase 3 (119). IFG-IR is frequently overexpressed in
carcinomas of breast, lung, colon, and prostate (120) and overexpression of IGF-IR reduces p53mediated apoptosis through a p53-Mdm2 feedback loop (121). In addition, IGF-IR signaling
inhibits apoptosis signal-regulating kinase 1 (ASK1) which is a MAP kinase kinase kinase
(MAPKKK) that is required for c-Jun N-terminal kinase (JNK) and p38 activation in response to
Fas and tumor necrosis factor (TNF) receptor stimulation in the extrinsic apoptotic pathway.
IGF-IR forms a complex with ASK1 and suppresses ASK-1-mediated stimulation of JNK/p38
and the induction of programmed cell death in a PI3K independent manner (122). The presence
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of multiple anti-apoptotic pathways may explain the efficacy of the IGF-IR in protecting cells
from apoptosis.

1.6.3.3

IGF-IR signaling in cell angiogenesis and metastasis

Angiogenesis (neovascularization) is a process by which new blood vessels are formed
from current blood vessels. This process is critically important for the growth and development
of tumors. As tumors enlarge, centrally located cells require sufficient oxygen and nutrients for
viability and the removal the waste during metabolism. In addition, it creates a new path for
cells to migrate to more distance organs. IGF-IR has been shown to increase VEGF expression
through an induction of hypoxia-inducible factor 1α (HIF-1α) via PI3K and MAPK pathways
(123), and therefore promotes endothelial cell proliferation. IGF-IR also cooperates with
integrins, αvβ3, and activates PI3K and MAPK signals in promoting angiogenesis and cell
metastasis (124-126). Angiogenesis is an obligate requirement for tumor cell invasion, migration,,
and metastasis.

Along with promoting angiogenesis, IGF-IR signaling contributes to the metastatic
process by affecting cell behavior, adherence, motility, and invasive ability. Cell-cell interaction
is tightly regulated by adhesion molecules such as E-cadherin, β-catenin and integrins. Activation
of PI3K/AKT via IGF-IR signaling has been shown to reduce epithelial markers, E-cadherin and
β-catenin, and therefore promote IGF-IR-induced cell motility (127). The reduction of cell
adhesion breaks down intracellular adherent junctions and changes cell behavior from an
epithelial cell type to a mesenchymal cell type. This process is called “epithelial-mesenchymal
transtion” (EMT). This is a classical transition when tumor cells are transformed to undergo
migration and invasion. In addition, IGF-I induces cell migration by promoting MMP production
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and thus promoting a degradation of the sorrounding extracellular matrix (ECM) (128), and
establishing a proper microenvironment for cell migration and invasion. MMPs have to be
activated by a proteolytic process and IGF-IR/PI3K/AKT promotes MMP protein activation by
increasing a proteolytic activator. MMP-14 is one of the proteolytic activators of MMP-2 (129).
MMP-2, MMP-7 and MMP-9 have been shown to free IGF via proteolytic cleavage of IGFBP3
(130-131), increasing IGF bioactivity and constitutively activating IGF-IR signaling.

1.6.3.4

Epidemiological studies of IGF/IGF-IR axis in prostate cancer

There is a positive correlation between the IGF signaling axis and prostate cancer. The
risk for prostate cancer was more than 4 fold higher in men with the highest circulating levels of
IGF-I (highest quartile) compared to the men in the lowest quartile (132). In addition, plasma
levels of IGF-I and IGFBP3 were the predictors of advanced prostate cancer (133). In a nested
case–control study within the Northern Sweden Health and Disease Cohort Study, subjects with
prostate cancer had significantly higher mean levels of IGF-I and IGFBP-3 compared to controls
(134). Furthermore, a higher ratio of IGF-I:IGFBP3 was associated with increased risk for
benign prostatic hyperplasia (BPH) (a potentially preneoplastic condition), while high serum
IGFBP3 levels were associated with decreased BPH risk (135). In addition, IGF-I levels and
IGF-IR expression increased significantly as the prostatic tissue transitioned from BPH to PIN to
malignancy, demonstrating a high correlation between the IGF axis and prostate tissue
morphology and tumor grade (136). These observations were supported by data showing stroma
adjacent to Gleason grade ≥7 tumors had higher expression of IGF-IR than the lower grade
tumors and benign epithelium (137). Chen et al. analyzed 96 studies and over 110,000 subjects
for the relationship between circulating levels and polymorphisms of IGF1 and IGFBP3 and
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cancer risk (138). They found increased levels of IGF-I significantly increased cancer risk by
15%, whereas increased IGFBP3 levels significantly decreased the risk of advanced prostate
cancer by 56%. Taken together, circulation of IGF and IGFBP as well as the expression of IGFIR may serve as biomarkers for prostate cancer development.

Controversially, some evidence showed that the IGF axis disrupts hormone ablation
therapy on prostate cancer patients. Before hormone ablation therapy, the IGF-I level was
correlated with bone metabolic disorder, but there was no relationship after hormone ablation
therapy (p=0.565). This result indicated that IGF axis may be inactivated during hormone
ablation therapy (139). The role of IGF-1/IGF-1R axis should be clarified.

1.6.4 HDACs mechanisms

Histone deacetylases (HDACs) are a family of proteins that are involved in cancer
development and have been a target for cancer therapy. There are several members in the HDAC
family and can be classified as class I, class II, class III and class IV. The class III subgroup is
also called known as sirtuins and depend on nicotinamide adenine dinucleotide (NAD1) for their
catalytic activity, exhibiting catalytic activities similar to ADP-ribosyltransferases or ADPcyclases. Some of the Class III members lack deacetylase activity.

Histone deacetylases of class I, class II and class IV are zinc-dependent amidohydrolases
and represent the classical activity of deacetylases. The function of HDACs is activated through
a zinc-based catalytic mechanism. At the transcription level, HDACs cleave acetyl groups from
lysine residues on histones, particularly histone H3 and H4. The removal of acetyl group
condensed the chromatin structure and decreases gene expression, epigenetically. Acetylation of
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histones are involved in chromatin assembly (140), DNA repair and recombination (141).
Therefore, accumulation of epigenetic changes results in the alteration of gene expression.

Histones are not the only substrates of HDACs, and growing evidence suggests that
HDACs function on the non-histone proteins such as p53 (142) and IRS-I (143). In addition,
non-protein molecules such as polyamines or metabolic intermediates might also be substrates of
HDACs (144).

Both acetyaltion and deacetylation have different effects on proteins. First, acetylation or
deacetylation on select lysine residues can affect protein stability by site competition for
ubiquitylation (145), protein-protein interaction (changes in configuration), and protein
localization. For example, deacetylated Ku70, a nuclear DNA-damage-response protein,
complexes with Bax, a pro-apoptotic protein, protecting cells from apoptosis. Bax dissociates
from acetylated Ku70 and translocates into mitochondria to activate intrinsic apoptosis (146).

Activity of classical HDACs is inhibited by zinc chelators, mainly thiols or hydroxamic
acid derivatives like TSA (trichostatin A) and SAHA (suberoylanilide hydroxamic acid, INN:
Vorinostat) (147). An increasing number of studies show that inhibition of HDACs suppress
tumorigenesis by increasing cell death and inhibit cell proliferation by altering the acetylation
status of chromatin and other non-histone proteins (Figure 1.2). Inhibitors of class I, class II and
class IV HDACs have been identified. Most of them are derived from the natural compounds and
some of them are artificially synthesized. These HDAC inhibitors have been used in the phase I,
phase II and phase III clinical trials on hematological malignancies and various solid tumors
(148-149). The combination of HDAC inhibitors with other anticancer agents associated with
traditional therapy may be a favorable clinical treatment.
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Figure 1.2 Anticancer effects of histone deacetylase inhibitors (HDACi) (149).

33

1.6.4.1

HDAC inhibitors in apoptosis

Inhibitors of HDACs have been found to have pro-apoptotic properties through either
intrinsic or extrinsic apoptosis. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL), death receptor 4 and 5 (Dc4 and Dc5), along with Fas-associated death domain (FADD)
initiate extrinsic apoptosis downstream by activating caspase 8 and caspase 10. Activation of
caspase 8 and caspase 10 cleave pro-caspase 3 and Bid, which engages the intrinsic apoptotic
pathway in the mitochondria. The involvement of TRAIL associated with HDAC inhibitor,
SAHA, results in cell death by activation of the caspase cascade and induction of mitochondrialmediated cascade (150). HDAC inhibitors and TRAIL synergize to induce caspase 3 activation,
internucleosomal DNA fragmentation, and promote mitochondrial damage (151). HDAC
inhibitors, sodium butyrate and TSA, had similar effects on prostate cancer cells. Inhibition of
HDACs decreased protein kinase casein kinase (PKCK) 2 activity, leading to caspase 2
activation and partial cleavage of caspase 8, sensitizing tumor cells to TRAIL-mediated cell
death (152). Most of the studies investigated show that HDAC inhibitors are associated with
TRAIL to synergize extrinsic and intrinsic apoptosis.

1.6.4.2

HDAC inhibitors in cell proliferation

Cell growth is tightly regulated via cell cycle, and growth is attenuated or terminated as a
result of cell cycle arrest. The cell cycle can be blocked by cell cycle inhibitors, such as the
cip/kip family and the INK4a/ARF (Inhibitor of Kinase 4/Alternative Reading Frame) family,
each of which is involved in regulating different phases of cell cycle. HDAC inhibitors have
been shown to increase the levels of p21WAF1/Cip1 and p27WAF1/Kip1 in vitro (153-157) and in vivo
(158-159). Induction of p21 is tightly linked cell cycle arrest mediated by HDAC inhibitors in a
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variety cell types through a p53-independent mechanism. This involves Sp1 binding sites in the
p21 promoter region (159-160). In G1/S phase, retinoblastoma (Rb) forms a repressor containing
HDAC and the hSWI/SNF, a member of E2F family. This complex inhibits transcription of genes
for cyclins E and A (161) while cyclins E and A are suppressed by p21 WAF1/Cip1 and p16INK4a. p21
WAF1/Cip1

and p16INK4a are both induced by HDAC inhibitors (162). In addition, p21WAF1/Cip1

inhibits the association of phospho-Rb and E2F, thereby reducing the activity of E2F on cyclin E
and CDK2, resulting in G1/S arrest.

1.6.4.3

HDAC inhibitors in angiogenesis and metastasis

The potential ability of HDAC inhibitors on tumor cell migration and invasion have been
validated in vitro. Cell adhesion molecules such as E-cadherin, β-catenin and integrins have been
reported to be regulated by HDAC inhibitors. TSA up-regulates integrins a4, b2 and b6 in
Hep3B cells, inhibiting cell migration (163). HDAC inhibitors markedly induced growth
response gene-1 (Egr-1), a Cys2-His2-typed zinc-finger transcription factor, and restored tight
junctions (TJs) in cancer cells. These results suggest that HDAC inhibitors increase cell-cell
adhesion. In addition, proteins that negatively regulate metastasis, such as thrombospondin- 1
(TSP-1), claudin-3 and E-cadherin were up regulated by HDAC inhibition and proteins that
positively regulate metastasis, such as IGF-1R and snail (an EMT promoter), were reduced in
human hepatocarcinoma cells (164). HIF-1α and VEGF were suppressed by TSA through an
inhibition of the PI3K-AKT/PKC/HDAC pathway (165). Inhibition of these angiogenic factors
inhibits endothelial cell migration, proliferation and angiogenesis (166-167). The same events
have been demonstrated in other models by using bovine aortic endothelial cells and chick
embryo (168). HDAC inhibitors such as FK228 (romidepsin), isolated from Chromobacterium
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violaceum, blocked hypoxia-induced proliferation, invasion, migration, adhesion, tube formation
and neovasculariztion (168).

1.6.4.4

HDAC and HDAC inhibitors in prostate cancer

Androgen receptor is an important transcription factor for cell growth and cell survival
whether in hormone-sensitive or in castrated-resistant prostate cancer. There is increasing
evidence demonstrating that AR is regulated by HDAC inhibitors. The effects of HDAC
inhibitors have been determined in AR-dependent and AR-independent prostate cancer cell lines
such as LNCaP, PC3 and CWR22Rv1 cells either in vitro or in vivo models. Valproic acid, an
HDAC inhibitor that has been used clinically, reduced LNCaP cell proliferation by 14% when
provided at physiological doses (0.45 mM) and abolished the growth promoting response of
androgens by reducing AR expression (169). Similarly, valproic acid reduced PC3 cells
proliferation by 40%, and the effects in both cell lines were associated with an increase of E-Cad
(169).

Inhibition of HDACs with a variety of inhibitors or through siRNA technology
suppresses transcriptional activity of the AR by inhibiting the assembly of co-activator/RNA
polymerase II complex to target genes. In addition, HDAC inhibition can also reduce AR protein
levels (170). In a CWR22Rv1 castrate-resistant prostate cancer xenograft model, LBH589
blocked tumor growth by 75% compared to control and reduced PSA gene expression (170). In
contrast, Lee et al. reported that extracts of allspice reduced LNCaP cell growth by reducing
histone acetyltransferase and histone acetylation through the inhibition of CBP/p300 (a protein
complex with histone acetyltransferase activity). This reduction in histone acetyltransferase
activity was accompanied by reduction in PSA gene expression, and a reduction of AR protein
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expression (171). Collectively, it is suggested that high activity of HDACs causes epigenetic
alterations (reductions in histone acetylation) and these changes are associated with an induction
of malignancy.

There are two important features of HDAC inhibitors for use in the clinical setting.
HDAC inhibitors are cytotoxic against tumor cells, but normal cells appear to be unaffected; and
HDAC inhibitors have multiple activities affecting multiple molecular pathways. For example,
they increase p21 expression via epigenetic regulation, and p53 through non-histone protein
acetylation. Overall, HDAC inhibitors repress cancer cell proliferation, cell survival, metastasis
and angiogenesis and induce cell apoptosis through transcriptional and post-translational
modulation (172).

Despite what we know about HDAC inhibitors, the functions of HDAC isoforms in
human tumors are not clear. Analysis of 192 samples of prostate carcinomas, revealed strong
expression patterns of the class I family of HDACs, where 70%, 74% and 95% of the tumor
samples had strong signals from HDAC1, HDAC2 and HDAC3, respectively. The expression of
these HDACs was associated with tumor cell proliferation, and HDAC1 and HDAC2
expressions were significantly correlated with Gleason score. High expressions of HDAC1, 2
and 3 were accompanied by an earlier PSA-relapse after radical prostatectomy, showing an
increase castrate-resistance (173). Therefore, HDACs might be a suitable target for treatment in
prostate cancer. FK228 (romidepsin) has been approved by US Food and Drug Administration
(FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) and it has been used in a phase II
clinical trial of progressing, metastatic, castration-resistant prostate cancer (CRPC), although
there was only minimal antitumor activity in these patients (174). However, the combination of
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HDAC inhibitor (vorinostat) and chemotherapy (doxorubicin) showed an antitumor effect
without additional toxicity associated with chemotherapy alone (175). The combination of
HDAC inhibitor SAHA (139) and radiation has been shown to enhance radiation-induced
cytotoxicity in DU145 cells (androgen-independent prostate cancer cell line) (176), and this
result provides a rationale for a combination therapy in further clinical trials.

1.7

Dietary components, phytochemicals, and prostate cancer

1.7.1 Anti-cancer properties of phytochemicals

Phytochemicals are non-nutritive components typically found in plants that have been
shown to have multiple anti-carcinogentic and anti-mutagenic properties. These compounds are
commonly used in the prevention and treatment of cancer/tumorigenesis using experimental
models in vitro and in vivo, and in human clinical trials. The mechanisms of action of these
phytochemicals involve multiple signaling pathways including suppression of PI3 kinase and
MAP kinase pathways and inactivation of transcriptional factor such as nuclear factor k B
(NFkB), resulting in cell cycle arrest and apoptosis.

1.7.1.1 Epidemiological and clinical evidences for an association between
phytochemicals and prostate cancer

Prostate cancer is currently the most commonly diagnosed solid malignancy and has
become the second leading cause of cancer-related deaths in men in most Western developed
countries (3) and the use of phytochemicals in prostate cancer might be one of the more
promising treatments. There is increasing evidence demonstrating dietary components, such as
phytochemicals, may have utility in reducing the incidence of prostate cancer. Dietary
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vegetables, fruits and medicinal herbs are rich in phytochemicals. Some studies indicated that the
increased intakes of vegetables and fruits can lower the incidence and/or progression of prostate
cancer. In an earlier multi-ethnic case-control study involving African-Americans, whites,
Japanese, and Chinese from the United States and Canada, intakes of legumes, yellow-orange
and cruciferous vegetables were inversely related to prostate cancer risk, but not tomatoes or
fruits (177). Carotinoids, including lycopene-rich vegetables, reduced incidence and advanced
forms of prostate cancer in a prospective cohort study and these effects were also observed in a
phase II clinical trial (178-179). Allium vegetables, including garlic, scallions, onions, chives
and leaks also decreased the risk of prostate cancer (180). In addition to vegetables and fruits,
consumptions of food containing soy and isoflavones reduced the risk of cancer in a case-control
study involving Chinese (181).

In addition to foods, common and medicinal herbs, including green tea, turmeric, etc.,
have been shown to have beneficial effects on reducing prostate cancer progression and
incidence. Green tea has been used in China for thousands of years and green tea and its
bioactive components reduce prostate cancer progression in different phases of the disease. In a
proof-of-principle clinical trial, sixty individuals with high-grade prostate intraepithelial
neoplasia (HGPIN) were randomly treated with green tea catechins (600 mg/day) or a placebo
for a year. Only one individual was diagnosed with a malignancy in the group receiving
catechins, while nine individuals in the placebo group developed prostate cancer (182). In a
short-term study involving twenty-six men with positive prostate biopsies who were
administered tea-derived polyphenols (1.3 g/day) , a majority of subjects had significant
reductions in serum levels of hepatocyte growth factor (HGF), VEGF, IGF-I/ IGFBP-3 ratio, and
PSA (183). These results indicated that the medicinal herbs or phytochemicals may have
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anticancer properties.

1.7.1.2 The anti-carcinogenetic mechanisms of phytochemicals

Carcinogenesis is a multiple step process involving tumor initiation, promotion, and
progression. Phytochemicals that are present in plants sources have been reported to possess anticarcinogenic activities through multiple pathways (Table 2.1). Basically, these phytochemicals
are classified into two categories: blocking agents and suppressing agents. Blocking agents
prevent carcinogen formation from precursors and prevent carcinogens from reacting in the
tissues. Suppressing agents inhibit, delay or reverse the expression of malignancy after exposure
to carcinogens (184-185). Some phytochemicals inhibit pro-carcinogenic activity to electrophilic
species or interaction with DNA and stimulate the detoxification of carcinogens. Other
phytochemicals suppress the latter steps of cancer (promotion and progression) and some
phytochemicals can act as both blocking and suppressing agents (186).

Phytochemicals, such as epigallocatechin-3-gallate (EGCG) and curcumin, have been
shown to coordinately regulate the expression of xenobiotic metabolizing enzyme genes (phase I,
II and III) and antioxidative stress genes (187-189), preventing tumor initiation by reducing procarcinogens, reactive intermediates or their activated metabolites and enhancing the cellular
defense system (187-188). In addition, phytochemicals have been shown to generate reactive
oxygen species (ROS) to disrupt the mitochondrial membrane potential and activate the intrinsic
apoptotic cascade. Phytochemicals, such as berberine, can increase the production of ROS by
increasing xanthine oxides in prostate cancer cells (12).
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Phytochemicals also act as suppressing agents and function on tumor promotion and
progression by coordinately regulating various signaling pathways, including growth factor
receptors pathways, stress-activated protein kinases pathways, nuclear factors signaling and the
regulation of the cell cycle and cell death.

1.7.1.2.1 Modulation of growth-factor receptors pathways by phytochemicals

Increasing evidence indicates growth factors and/or growth factor receptors are over
expressed in tumor cells and contribute to cell proliferation and survival signals. Phytochemicals
have been shown to reduce growth factor expression and down regulate the expression and
activity of growth factor receptors. Curcumin was the first phytochemical found to inhibit
tyrosine phosphorylation of epidermal growth factor receptor (EGFR) (190-191) and human
epidermal growth factor receptor 2 (Her2/neu) (192). It was also found that curcumin sensitized
prostate cancer cells to apoptosis induced by TRAIL by activating c-Jun N-terminal kinase
(JNK), inhibiting IκBα/NFκB activation, and suppressing AKT signaling pathways (193-196),
resulting in activation of the caspase cascade, and thus cell death (197). The ability of curcumin
to sensitize cells to TRAIL was demonstrated in a xenograft model using TRAIL-resistant
LNCaP prostate cancer cells. Mice were provided TRAIL (15 mg/kg) in the presence or absence
of curcumin (30 mg/kg body weight). Compared to TRAIL alone, curcumin sensitized LNCaP
cells and by reducing VEGF, VEGFR2, NFκB-induced COX2, MMP2 and MMP9 while
inducing death receptor 4 and 5, p21 and p27 (198).

Additionally, the proliferative EGFR-dependent Erk1/2 signaling pathway can be
inhibited by EGCG (199). EGCG also inhibited IGF-1-induced cell growth in androgendependent and androgen-independent prostate cancer cells (200-201) and inactivated
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VEGF/VEGFR axis by suppressing the expression of hypoxia-inducible factor (HIF)-1α,
reducing angiogenesis (202). The reductions in growth-factor receptors pathways were also
observed in other phytochemicals such as resveratrol (15), gingerol (203), baicalein (14),
berberine (204).

1.7.1.2.2 Modulation of stress-activated pathways by phytochemicals

Extracellular stresses activate several pathways including stress-activated protein kinases
and p53 expression. Stress-activated protein kinases include JNKs and p38 mitogen-activated
protein kinase (MAPK). They are activated in response to the extracellular stimuli, such as UV,
DNA-damage agents or pro-inflammatory factors. These kinases function as either pro-apoptotic
protein kinases or anti-apoptotic kinases (205). Curcumin has been shown to have multiple
anticancer properties including induction of JNK and p38 MAPK, cytochrome c release from
mitochondria and activation of caspases 3, 8 and 9 in androgen-independent PC3 prostate
cancer cells (10). Similar results were observed when PC3 cell were treated with a variety of
flavonoids ( kaempferol, apigenin, genistein and naringenin). Inductions in phospho-JNK,
phospho-Erk and increases in activator protein 1 (AP-1), a downstream transcription factor of
JNK, was observed in PC3 cells (206). Transcription factor AP-1 plays an important role in
carcinogenesis and regulates a variety of its target genes, such as EGFR, cyclin D1, Bcl-2 and
MMPs (207-210). In androgen-dependent LNCaP prostate cancer cells, protoapigenone, a
natural derivative of the flavanoid apigenin, showed similar effects on JNK and p38 MAPK
activations (211). These studies indicate that the treatments of flavonoids can result in activation
of JNK and in cell death.
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In addition to AP-1 activation through JNK or p38 MAPK signaling, NFκB is a rapidactivated stress-responsive transcription factor, inducing the transcription of various genes
encoding cytokines, membrane proteins, other transcription factor, inhibitors of apoptosis and
pro-inflammatory factors (212). NFκB activation is initiated through a removal of inhibitory
protein (IκB) from the NFκB/IκB complex by a variety of stimuli including TNFα, LPS, UV or
IR and DNA damage (213). In cervical cancer cells, curcumin reduced TNFα-induced NFκB
activation and reduced cyclooxygenase 2 (COX-2) expression through a blockage of IκBα
phosphorylation, increasing degradation (214). In addition, Curcumin has anti-inflammatory
property by reducing leukocytes recruitment mediated by TNFα-induced NFκB activation (215).
Resveratrol has also been shown to reduce NFκB expression by targeting protein NAD(P)H
dehydrogenase and quinone 2 (NQO2) in CWR22Rv1 prostate cancer cells (216). Resveratrol
also inhibited TNFα-induced Erk and JNK activation and reduced p65 phosphorylation and
nuclear translocation (217). Other phytochemicals including EGCG (218), genistein (219), [6]gingerol (11), capsaicin (220) and caffeic acid phenethyl ester (CAPE) (221) have the similar
inhibitory effects on NFκB activation induced by UV light, TNFα, 12-O-tetradecanoylphorbol13-acetate (TPA) or phorbol 12-myristate 13-acetate (PMA).

Tumor suppressor gene, p53, inhibits tumorigenesis in responding to cellular genotoxic
stresses, such as UV, IR or non-genotoxic stress, such as phytochemicals (222). Activation of p53
induces cell cycle arrest and cell apoptosis resulting in reducing cancer cell growth. Lack of p53
is associated with an increase of tumorigenesis, allowing an accumulation of mutations in
damaged cells and blocking the apoptotic responding to genotoxic stress. Phytochemicals,
EGCG, genistein, quercetin, indole-3-carbinol, curcumin and resveratrol, have been shown to
increase p53 expression, induce cell cycle arrest and cell death in both androgen-dependent
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LNCaP and androgen-independent PC3, DU145 and CWR22Rv1 prostate cancer cells (223-228).
Activation and induction of p53 by phytochemicals such as resveratrol and caffeine are regulated
by MAP kinases on p53 phosphorylation at serine 15, which stabilize and activate p53 (229-231).
Resveratrol inhibits the growth of LNCaP prostate cancer cell by activating p53-responsive
genes such as p21WAF1/CIP1, p300/CBP and Apaf-1 (232). Additionally, in LNCaP cells, cell
apoptosis is promoted and the cell growth is inhibited by EGCG treatment along with induction
of p53, reduction of NFκB, and suppression of Bcl-2 (233). Activation and phosphorylation of
p53 can be induced through ataxia teleangetasia mutated and ATM-related kinase (ATM/ATR)
pathway by genistein and enhances the sequence-binding specificity of p53 on target DNA (228).
While p53 is up-regulated and activated by phytochemicals, activated p53 promotes cell cycle
arrest and cell death, thus inhibiting tumorigenesis.

1.7.1.2.3 Induction of cell cycle arrest and apoptosis by phytochemicals

The majority of phytochemicals reduce tumor cell proliferation by inducing cell cycle
arrest and increasing cell death. Cell cycle mediators and cell death promoters are modulated by
phytochemical in a variety of cancer cell lines (234). Resveratrol is one of the more widely
studied phytochemicals. When LNCaP, DU-145, PC-3, and JCA-1 human prostate cancer cells
were treated with resveratrol, G1/S transition phase of the cell cycle was inhibited and cell
apoptosis was induced (235). The inhibition effects of resveratrol on cancer cell growth have
been found in other cells including breast, colon, pancreas, and squamous cell carcinoma etc.
Resveratrol increased cell cycle inhibitors, p21 and p27, and tumor suppressor gene, p53, along
with reductions in cell cycle promoter, cyclin D1 and cyclin E, anti-apoptotic proteins, Bcl-2 and
Bcl-xL. Proliferative AKT signaling was also decreased by resveratrol (236). p21 and p27 inhibit
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cell cycle regulators, cyclin/ cyclin-dependent kinase, thus blocking cell cycle transition. In
addition, it has been shown that resveratrol enhances apoptosis induced by TRAIL through
induction of cellular inhibitor-of-apoptosis proteins (cIAPs) and Bax expression (237, 13, 238),
and reduction of AKT phosphorylation (239) in androgen-dependent and androgen-independent
prostate cancer cells.

In animal models, green tea and its bioactive compounds, catechins, have been shown to
inhibit tumor cell growth. In a CWR22Rv1 athymic nude mouse model, green tea polyphenols
(GTP) and EGCG attenuated tumor growth by extending the length of time to reach final tumor
size by 38% and 108%, respectively. Reduced Bcl-2 expression and increases in active caspase
3, cleaved PARP and Bax expression indicated EGCG and GTP inhibited prostate cancer cell
growth by increasing apoptosis (240). The mechanisms of EGCG on prostate cancer cell growth
have been investigated using PC3 and LNCaP cells. EGCG induces cell cycle arrest by
increasing p53-dependent p21 expression and promotes cell death by reducing pro-proliferative
Bax expression and NFkB transcriptional activity (241, 233), thereby inhibiting cell growth.
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Table 1.3 Summary of molecular targets by curcumin and EGCG in prostate cancer animal and
cell models

phytochemicals

doses

Molecular targets

Animal models/
cell types
LNCaP; PC3

Ref.

Curcumin

5-50 μM

↓ EGFR

10 μM

No changes on Her2/neu, PARP, STAT3
DNA binding activity

PC3 , DU145

(242)

10-50 μM

↓ IκBα/NFκB;

LNCaP, PC3

(193-194)

(190)

↓ p-AKT, Bcl-2, Bcl-xL, XIAP;
↑ caspase
25-100 μM

↑p-p38, p-JNK, caspase 3, 8, 9, Cyt C,
AIF

PC3

(10)

5-30 μM

↓p-AKT

LNCaP

(227)

LNCaP in
Athymic (nu/nu)
nude mice

(198)

↓Bcl-2, Bcl-X
↑ROS
↑p53, Bax, Bak, PUMA, Noxa, Bim, Cyt
c, Smac/DIABLO, Omi/HtrA2, caspase
3;
↑Acetylation of histone H3, H4

30 mg/kg

↓ VEGF, VEGFR-2, MMP2, MMP9,
COX2, p65;
↓ cyclin D1, Bcl-2, Ki67;
↑ DR4,DR5, Bax;
↑ p21WAF-1, p27KIP-1
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Table 1.3 Continued.
phytochemicals

doses

Molecular targets

Ref.

↓ IGF1, AKT,

Animal models/
cell types
LNCaP, DU145,
PrEC

EGCG

5-20 μM

2.5 μM

↓AR;

CWR22v1

(226)

LNCaP, DU145

(225)

LNCaP

(241, 233)

CWR22Rnu1 in
Athymic (nu/nu)
nude mice

(240)

(200-201)

↑p53
5-40 μg

↓ cyclin D1, cyclin E, cdk2, cdk4, cdk6;
↑ p16INK4a,p18INK4c, p21WAF-1, p27KIP-1

20-80 μM

↓ NFκB;
↑p53, p21WAF-1, Bax, caspase 3, 8, 9

1 mg/ day

↓ PSA, tumor size;
↓ VEGF, Bcl-2;
↑ caspase3, PARP, Bax
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1.7.1.3 Epigenetic anti-cancer effects of phytochemicals

Phytochemicals have been shown to regulate gene expression epigenetically via DNA
methylation and histone acetylation and methylation. Methylation on CpG site in DNA by DNA
methyltransferases (DNMTs) is an epigenetic silencing mechanism on tumor suppressor genes
during tumorigenesis, and removal of methyl groups from the CpG islands allows binding of
transcriptional proteins. This removal can be induced by phytochemicals such as EGCG,
curcumin and others. In addition, histone modification is another key feature of epigenetic
regulation through acetylation and methylation. These modifications on histones allow the
loosing of the chromatin structure resulting in the recruitment of transcriptional factors on DNA,
thus increasing gene expression. A number of phytochemicals have been shown to modify
histones, enhancing the expression of tumor suppressor genes, such as p21. It has been
demonstrated that the epigenetic regulation by diet is inherited in mice (243), indicating that
dietary factors are able to influence gene expression.

1.7.1.3.1 DNA methylation

One of the epigenetic changes in prostate cancer is DNA methylation. More than 30
genes have been identified to have abnormal methylation on DNA promoters including the genes
related to the cell cycle, hormone response, and DNA repair (244). For example, gluthathione-Stransferase pi (GSTP1) is involved in detoxification and protects DNA from reactive
electrophilic intermediates. Hypermethylation results in gene silencing and this phenomenon has
been found in LNCaP, C4–2B, PC-3, DU-145, LAPC-4, and VCaP human prostate cancer cells.
This observation is supported in metastatic prostate cancer tissues compared to normal tissue
(245). Green tea polyphenols (GTPs) and its bioactive compound, EGCG, are reported to re48

expression of GSTP1 (246). DNA methyltransferase 1 functions by adding methyl groups on the
DNA promoter region, resulting in DNA silencing. The activity of DNMT1 in LNCaP, MDA,
PCa 2b and DU145 human prostate cancer cell lines were suppressed by EGCG (247). EGCG
binds to catalytic residues on DNMT1 through hydrogen bonding and blocks the active site of
DNMT1, reducing DNMT1 activity (248). In addition to the inhibitory effect of EGCG on
DNMT1 kinetic activity, the DNMT1 inhibitor, S-adenosyl-L-homocysteine (SAH), is increased
by EGCG by an enzymatic methylation reaction (249). These results explain the epigenetic
regulation mechanisms of EGCG in vitro. However, the underling mechanisms of EGCG via
mediation of DNMTs on tumor suppressor genes have not been illustrated in prostate cancer
patients yet.

1.7.1.3.2 Histones acetylation and methylation

Histone acetylation and methylation are the principle regulators of epigenetic regulation
of gene expression involving histones. The actions of acetylation and methylation on specific
lysine or arginine residues in histones H3 and H4 are reversible processes that are modulated by
histone acetyltransferases (81), HDACs and histone methyltransferases (HMTs) (250). Histone
deacetylases are the new target for cancer chemotherapy, including prostate cancer, with elevated
expressions of HDAC1, 2 and 3 (173). The use of HDAC inhibitors, such as TSA, has been
shown to inhibit HDAC expression and activity and induce the cell cycle inhibitor, p21. This
results in cell cycle arrest and cell death (using in vitro models) (160), and thus HDACs
inhibitors are a therapeutic target for the inhibition of tumor progression. Important to this
discussion is the fact that phytochemicals appear to act as HDAC inhibitors, arresting tumor cell
growth and promoting cell death. Isothiocyanate is found in cruciferous vegetables, such as
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broccoli, and has been shown to inhibit HDACs in vitro, in vivo and in tissues from human
subjects (251). For example, consumption of broccoli sprouts (68 g), containing 105 mg of the
isothiocyanate sulforaphane, reduced plasma HDAC activity in human subjects after 3 hours
(252). In a xenograph mouse model using PC3 human prostate cancer cells, sulforaphane (443
mg/kg diet for 21 days) reduced tumor growth, inhibited HDAC activity, and increased
acetylation of histones H3 and H4 (252).

Regulation of histone acetylation is a balance between the removal and incorporation of
acetyl groups mediated by HDACs and histone acetyltransferases. Induction of histone
acetyltransferases counter balances the actions of HDACs. Ideally, if hyperacetylation of
histones were the overall goal, then it would be most desirable to use a product that inhibits
HDAC function and enhances histone acetyltransferase activity. The classical HDAC inhibitor
TSA has been shown to increase acetylation of CBP/p300 and thus increase its acetyltransferase
activity (253-254). The mechanism of activation is through MAP kinase signaling (255).
Curcumin has been shown to increase this pathway via MAP kinase phoshporylation with
concomitant induction of p21 expression, negatively regulating the cell cycle (256). This effect
of curcumin to inhibit tumor cell growth is supported by similar results in LNCaP prostate cancer
cells. Curcumin inhibited ntunor growth and induced the acetylation of histones H3 and H4 (227).

In addition to histone acetylation, methylation on specific lysine or arginine residues in
histones H3 and H4 by HMTs is another process either to activate or to repress gene expression.
When compared to post-treatment (radiotherapy + hormone therapy) plasma levels of circulating
histone H3 lysine 27 trimethylation (H3K27me3) from organ confined (n=22), locally advanced
(n=11), and metastatic (n=28) prostate cancer patients, the median level of plasma H3K27me3 in
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the patients with metastatic PCa was lower than patients with localized or locally advanced
prostate cancer (257), indicating that histone methylation is associated with progression of the
disease. This result is consistent with a finding that JMJD3 (defined as a histone demethylase) is
upregulated in advanced and metastatic prostate cancer patients (258). JMJD3 and H3K27me3
might be used as biomarkers of advanced of prostate cancer.

1.7.2 The use of phytochemicals in combination on prostate cancer

Consumption of whole fruits, vegetables and whole grain is strongly associated with a
reduction of prostate cancer risk (180, 177, 259). The effective bioactive compounds in the fruits,
vegetables and whole grains have been identified. The molecular mechanisms of these bioactive
compounds on tumorigenesis are well studied using experimental models in vitro and in vivo
(260, 198, 240, 185). However, it is believed that single nutrients or phytochemicals when used
at physiological concentrations, do not have the same effects as the whole fruits, vegetables and
whole grains as reported in epidemiological studies. In a 12- year randomized, double-blind,
placebo-controlled trial of beta-carotene (50 mg/d on alternate days), Hennekens et al. found that
the participants receiving beta-carotene had significantly higher beta-carotene concentrations in
plasma than those given placebo, but there were no significant differences in the number of cases
of lung cancer, or with other cancers, including colon/rectum, prostate , stomach, pancreas, brain,
or with various types of cancers, such as melanoma, leukemia, or lymphoma (261). These results
suggest that a single compound might as bioactive against tumorigenesis as compared to the food
it is found in. One of the possible strategies is the use of combinations of bioactive compounds,
whereby combinations may act synergistically to inhibit tumor growth. For example, when tea
polyphenols were provided to men with positive prostate biopsies, there was a significant
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reduction in serum PSA levels, but this effect was not observed with isolated catechins (183). In
a CWR22Rv1 athymic nude mouse model, green tea polyphenols attenuated tumor growth
compared to mice receiving one of its bioactive components, EGCG (240). A combination of soy
phytochemicals (5 g/kg diet) and tea (15 g tea leave/L drinking water) for 10 weeks showed a
synergistic inhibition on prostate tumor growth, metastasis and angiogenesis in LNCaP prostate
cancer xenograft mice (262). The same effects have been observed in other cancers, such as lung
and colon in mouse models (263-264). These synergistic effects of a combination of
phytochemicals may explain the efficacy of fruits and vegetables.

1.7.2.1

An example of the use of phytochemicals in combination, Zyflamend®

Zyflamend® is a multi-herb extract with anticancer properties. Extracts from each herb
contain a variety of bioactive phytochemicals (i.e., berberine, curcumin, epigallocatechin gallate,
resveratrol, etc), with known efficacy. The individual chemistries have been shown to increase
cell death and suppress cell proliferation via a variety of mechanisms (10, 265, 12, 203, 202, 1415). Therefore, their unique combination could result in additive or synergistic effects at
relatively low concentration. Zyflamend® appears to provide clinical improvement to patients
diagnosed with HGPIN, an early preneoplastic form of the disease. In a phase I clinical study, it
was reported that 48% of HGPIN patients had a 25-50% reduction in PSA levels and a reduction
in NFκB expression after a 18-month Zyflamend® (2.3g/d) (266-267). Using In vitro studies,
Zyflamend® reduced the growth of androgen-dependent LNCaP cells and this reduction was
associated with an elevated expression of p21 and apoptosis (as indicated an induction of PARP
cleavage and caspase 3 activity). Androgen receptor expression was also reduced by
Zyflamend® (268). In PC3 cells, Zyflamend® reduced Rb phosphorylation and thus blocked
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G2/M phase in the cell cycle. The reduction of Rb was related to inhibition of 12-lipoxygenase
(269). These anticancer properties of Zyflamend® were also observed in other cell models,
including human non-small cell lung carcinoma (H1299), human myelogenous leukemia (KBM5), and human multiple myeloma (U266) cells (suppressing osteoclastogenesis). Zyflamend®
induced cell cycle arrest and apoptotic and anti-angiogenetic gene expression by repressing
NFκB and its downstream genes, such as Bcl-2, Bcl-xL, FADD-like interleukin-1β converting
enzyme /caspase-8 inhibitory protein (270). However, the anticarcinogenic properties of
Zyflamend® on various stages of advance prostate cancer stages and the progression of the
disease from androgen-dependent to castrate-resistant growth in conjunction with hormone
deprivation has yet to be explored. Because of the diversity of chemo-preventive phytonutrients
in Zyflamend®, the use of Zyflamend® as an adjuvant to standard therapies, such as hormone
ablation therapy, seems promising.

1.8 Summary

Prostate cancer is a complicated disease involving multiple mechanisms and using a
therapy that has a specific target may not be as effective as a strategy that takes advantage of the
complexity associated with foods and herbs, thereby simultaneously affecting many signaling
pathways.

In this study, we decided to use a mixture of the extracts of ten individual herbs,
Zyflamend®, many of which having anticancer properties. We chose only to use human
equivalent does when provided in a diet, and concentrations we believed to be physiologically
relevant (in vitro). This was important to insure some translatability. We chose a human prostate
cancer cell line model, CWR22, that shared important characteristics related to the progression
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of human prostate cancer. We would like to discover if this mixture can reduce prostate cancer
growth and delay progression in a model of advance prostate cancer in the presence or absence
of androgens.

1. Determine the effects of Zyflamend® on androgen-dependent tumor growth in vivo.
2. Determine the effects of Zyflamend® on tumor regression in conjunction with
hormone deprivation in vivo.
3. Determine the effects of Zyflamend® on castrate resistant tumor growth in vivo and
in vitro.
4. Determine underlying molecular mechanisms associated with some of these effects.
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Chapter II
Epigenetic Regulation of p21 and Chemopreventive Effects of a
Combination of Herbal Extracts in Castrate-Resistant Prostate
Cancer
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Abstract
Zyflamend, a mixture containing extracts of ten common herbs, has been shown to cause
regression of early stages of prostate cancer in clinical trials. The current experiments were
designed to investigate its effects on advanced prostate cancer. Zyflamend® inhibited growth of
human CWR22Rv1 prostate cancer cells by increasing the expression of the cell cycle regulators
p21 and p27 through a p53-independent mechanism. Overexpression of p21 by Zyflamend® was
associated with a suppression of class I and II histone deacetylases (HDACs) and an induction of
CBP/p300 histone acetyl transferase activity by up regulating Erk-1/-2 and Elk-1. These effects
were not observed with the individual herbal extracts. Our results suggest the extracts of this
herbal combination inhibits castrate-resistant prostate cancer cell growth epigenetically by
coordinately affecting multiple signaling pathways involved in histone acetylation.

90

2.1

Introduction

Prostate cancer (PrC) is currently the most commonly diagnosed solid malignancy and
has become the second leading cause of cancer-related deaths in men in most Western developed
countries (1). Metastatic PrC is defined as the spread of PrC cells to secondary sites (i.e., bone,
lung, etc). Once tumors become metastatic, they are very difficult to treat, and prognosis is poor
with a 31% 5-year survival rate (2). For the most part, PrC is temporarily responsive to hormone
deprivation therapy as prostate epithelial cells are dependent on androgens for growth. While
treatment with hormone deprivation results in tumor regression and clinical stabilization, the
disease eventually relapses, with invariable fatal results within two years. Therefore, a critical
barrier in treating advanced PrC is finding effective treatments for castrate-resistant forms of the
disease. The CWR22Rv1 PrC cell line was chosen for the experiments because it represents a
very late stage of PrC (3). These cells can grow in the presence or absence of androgens, produce
prostate specific antigen (PSA) and express a functional androgen receptor (3) and, as such, these
cells are considered to be a castrate-resistant cell line. Similarly, PrC in patients whose disease
has relapsed following androgen ablation therapy expresses androgen receptors and produces
PSA.

The use of herbs, botanicals and their bioactive components have been shown to be
effective in many tumor cells lines in vitro and in vivo by inhibiting cell and tumor growth. The
use of herbal extracts in combination potentiates their actions, resulting in significant activity
when any single agent has no effect (4-7). Zyflamend®, a polyherbal preparation derived from
the extracts of ten common herbs, appears to provide clinical improvement to patients diagnosed
with high grade prostatic intraepithelial neoplasia (HGPIN), a preneoplastic form of the disease
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(8). In addition, Zyflamend® has been shown to reduce proliferation in a variety of PrC cell lines
by modulating genes that impact the cell cycle and apoptosis (9-11). Of particular interest to our
laboratory is the effect of Zyflamend® on castrate-resistant PrC.

In this study, we investigated the epigenetic effects of Zyflamend® on expression of the
cell cycle regulator p21 and concomitant inhibition of cell proliferation. Expression of p21 is
regulated, in part, by histone acetylation as mediated by histone deacetylases and histone acetyl
transferases. This work was designed to explore some of the molecular mechanisms behind
epigenetic regulation and the anti-carcinogenic effects of Zyflamend®.

2.2

Materials and Methods

2.2.1 Zyflamend®

Zyflamend® (New Chapter, Brattleboro, VT) is derived from the extracts of ten different
commonly consumed herbs (w/w): holy basil (12.8%), turmeric (14.1%), ginger (12.8%), green
tea (12.8%), rosemary (19.2%), hu zhang (10.2%), barberry (5.1%), oregano (5.1%), baikal
skullcap (2.5%), and Chinese goldthread (5.1%).

2.2.2 Cell Culture

Human prostate cell lines, RWPE-1, LNCaP, PC3 and CWR22Rv1, were purchased from
American Type Culture Collection (Rockville, MD). RWPE-1 cells were maintained in complete
medium containing keratinocyte serum free medium supplemented with bovine pituitary extract
(BPE) (0.05 mg/ml) and human recombinant epidermal growth factor (hEGF) (5 ng/ml). LNCaP,
PC3 and CWR22Rv1 cells were maintained in RPMI 1640 media supplemented with 10% fetal

92

bovine serum (FBS) under an atmosphere of 5% CO2 at 37oC. Cells were harvested with the
addition of 0.25% trypsin with 0.02% EDTA during the exponential growth phase. For the
experimental treatments, cells were cultured in RPMI 1640 media supplemented with 0.05%
fetal bovine serum containing Zyflamend® or individual herbal extracts (ginger, rosemary,
turmeric, Chinese goldthread, holy basil, hu zhang, barberry, green tea and baikal skullcap) (each
supplied by New Chapter, Inc, Brattleboro, VT) reconstituted in dimethyl sulfoxide (DMSO) for
cell proliferation assay, mRNA extraction and protein isolation. For inhibitor experiments,
CWR22Rv1 cells were pretreated with U0126 (Erk inhibitor) (Cell Signaling Technology, Inc.,
Danvers, MA) at a dose of 2 μM for 30 minutes and subsequently treated with Zyflamend® (200
μg/mL) for 24 hr. For histone deacetylase (HDAC) experiments, trichostatin A (TSA) (a general
HDAC inhibitor) was added alone at various concentrations (0, 0.1, 0.5, 1.0 μM) or in
combination with Zyflamend® (200 μg/mL) for 24 hours. In all experiments, 0.1% DMSO was
used as the vehicle control.

2.2.3 Cell Proliferation

The MTT assay [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide]
(Andwin Scientific, Addison, IL) was used to assess relative cell growth and viability, following
the manufacturer‟s instructions (Promega, Madison, WI). Cells (1×104 cells of RWPE-1,
LNCaP, and CWR22Rv1, and 5×103 cells of PC3) were plated in 96-well plates in a volume of
100 μl culture medium. The culture medium contained various concentrations of Zyflamend®
(0, 40, 80, 100, 150, 200 μg/mL) or individual herbal extracts (10.2 μg/ml ginger, 15.4 μg/ml
rosemary, 11.3 μg/ml turmeric, 4.1 μg/ml Chinese goldthread, 10.2 μg/ml holy basil, 8.2 μg/ml
hu zhang, 4.1 μg/ml barberry, 10.2 μg/ml green tea, 2.0 μg/ml baikal skullcap; equivalent to
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those doses in 200 μg/ml Zyflamend®). Cell proliferation was determined at 0, 24, 48, 72, 96 hr
post incubation. At each time point, a mixture of MTT:complete medium (1:10, v/v) was added
and incubated at 37℃ for 4 hr in a CO2 incubator (5%). Absorbance (at 540 nm) was measured
on a SpectraCount microplate photometer (Perkin Elmer Inc, Waltham, MA).

2.2.4 BrdU incorporation Assay

Cells (1×104 cells of CWR22Rv1) were plated in 96-well plates and treated with various
concentrations (0, 100, 150 and 200 μg/ml) of Zyflamend® for 48 hr and followed by a BrdU
incorporation assay to assess relative DNA synthesis following the manufacturer‟s instructions
(EMD Biosciences, Inc., Darmstadt, Germany). After Zyflamend® treatment, cells were treated
with BrdU for 4 hr and the BrdU incorporation was measured on a FluoroCount microplate
photometer (Perkin Elmer Inc, Waltham, MA) at a 340 nm excitation and a 460 nm emission.

2.2.5 Down regulation of p21 by small interfering RNA

CWR22Rv1 (1.5×105 cells per well in 6-well plates, in serum-free RPMI 1640 media)
were transfected with validated p21 small interfering RNA (siRNA) or Stealth™ siRNA
negative control (Invitrogen, Carlsbad, CA) (100 pmole each) using Lipofectamine 2000™
transfection reagent (Invitrogen, Carlsbad, CA) following the manufacturer‟s instruction. Six
hrs post transfection, cells were cultured with RPMI 1640 media containing 10% FBS overnight.
After recovery, media was replaced with 0.05% FBS media containing vehicle or Zyflamend®
(200 μg/ml) for 24 hr at 37 ℃. The total RNA was harvested for quantitative real-time
polymerase chain reaction (qRT-PCR) and cell number was determined.
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2.2.6 Overexpression of p21

pRc/CMV-p21 (Addgene Inc., Cambridge, MA), containing full length wild-type p21
cDNA, was used to overexpress p21. CWR22Rv1 cells (1.5×105 cells per well in 6-well plates)
were plated overnight. pRc/CMV-p21 or pRc/CMV (empty vector) were transfected using
Lipofectamine 2000™ reagent in serum-free RPMI 1640 media. Transfected cells were selected
by treatment for two weeks with neomycin (50 μg/ml) and subjected to the MTT cell
proliferation assay. p21 protein expression in the transfected cells was examined by western blot.

2.2.7 RNA isolation and quantitative RT-PCR

Total RNA was isolated from CWR22Rv1 cells using Trizol reagent (Invitrogen,
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100%
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water.
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc.
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™
(Thermo Scientifc Wilmington, DE). Total RNA (2 μg) from each sample was mixed with
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System,
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR
amplification with primer sets (2.5 μM) of p21 sense, 5‟-TGGAGACTCTCAGGGTCGAAAA-3‟
and antisense, 5‟- CCGGCGTTTGGAGTGGTA-3‟, p27 sense, 5‟CGGTGGACCACGAAGAGTTAA-3‟ and antisense, 5‟-GGCTCGCCTCTTCCATGTC-3‟,
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HDAC1 sense, 5‟-ACCGGGCAACGTTACGAAT-3‟ and antisense, 5‟CTATCAAAGGACACGCCAAGTG-3‟, H DAC2 sense, 5‟TCATTGGAAAATTGACAGCATAGT-3‟ and antisense, 5‟CATGGTGATGGTGTTGAAGAAG-3‟, HDAC3 sense, 5‟- TTGAGTTCTGCTCGCGTTACA3‟ and antisense, 5‟-CCCAGTTAATGGCAATATCACAGAT-3‟, HDA4 sense, 5‟AATCTGAACCACTGCATTTCCA-3‟ and antisense, 5‟GGTGGTTATAGGAGGTCGACACT-3‟, HDAC5 sense, 5‟TTGGAGACGTGGAGTACCTTACAG-„3 and antisense 5‟GACTAGGACCACATCAGGTGAGAAC-3‟, HDAC6 sense, 5‟TGGCTATTGCATGTTCAACCA-3‟ and antisense 5‟-GTCGAAGGTGAACTGTGTTCCT-3‟,
HDAC7 sense, 5‟-CTGCATTGGAGGAATGAAGCT-3‟ and antisense 5‟CTGGCACAGCGGATGTTTG-3‟, were examined. Amplification was performed using a
standard thermocycle program beginning with an initial temperature at 94°C for 1 min followed
by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was examined
in triplicate and the amounts of PCR product were normalized with 36B4, 5‟TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as
the internal control.

2.2.8 Protein degradation

CWR22Rv1 cells were cultured with RPMI 1640 medium containing Zyflamend® (200
μg/ml) for 24 hr to induce p21 expression. Cells were then cultured ±Zyflamend® for an
additional 24 hr. In addition, cells were treated with Zyflamend® (200 μg/ml) for 24 hr prior to
adding cycloheximide (10 μM) to terminate protein synthesis for an additional 0, 0.5, 1, 1.5, 2, 4
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hr in the continued presence or absence of Zyflamend® (200 μg/ml) and harvested for protein
analysis.

2.2.9 Western blotting

CWR22Rv1 cells were lysed in the presence of cell lysis buffer (Cell Signaling
Technology®, Inc. Danver, MA). Protein content of the lysates was quantified by BCA protein
assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (20 μg) were fractioned by 8~12%
SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by electroblotting.
The membranes were blocked using 5% nonfat dry milk in 0.1% Tris-buffered saline-Tween-20
(TBST) for 1 hour at room temperature and incubated in TBST containing primary antibodies
overnight at 4°C. The membrane was incubated with anti-mouse or anti-rabbit secondary
antibody conjugated with horseradish peroxidase (HRP) (Cell Signaling Technology®, Inc.
Danver, MA). Protein expression was detected with a Pierce ECL Western Blotting detection
system. Each membrane was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ).
Antibodies of p21, p27, p53, cyclin D1, cyclin E, HDAC1-7, Erk, phospho-Erk, Elk-1 (Cell
Signaling Technology®, Inc. Danver, MA), phosphor-Elk-1 (GenScript USA, Inc. Piscataway,
NJ) were used. Actin (with anti-β-actin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA)) was used as the control.

2.2.10 HDAC activity assay

CWR22Rv1 cells were lysed in the presence of cold lysis buffer (10 mM Tris-HCl, pH
7.5, 10 mM NaCl, 15 mM Mg2Cl2, 250 mM sucrose, 0.5% NP-40, and 0.1 mM EGTA). Nuclei
pellets were separated through a sucrose cushion (30% sucrose, 10 mM Tris-HCl, pH 7.5, 10 mN
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NaCl, and 3 mM Mg2Cl2) and resuspended in extraction buffer (50 mM HEPES, pH 7.5, 420
mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA, and 10% glycerol). The nuclei suspension was
sonicated on ice for 30 seconds and then the supernatant was stored at -80°C. An aliquot (30
μg/10 μl) of the nuclear extracts was used for HDAC activity assay as per manufacturer‟s
instructions (Cayman Chemical, Ann Arbor, MI). The assay was measured using an excitation
wavelength of 340 nm and an emission wavelength of 460 nm (FluoroCount, Perkin Elmer Inc,
Waltham, MA).

2.2.11 Statistic analysis

The results are presented as mean ± SEM and the mRNA results are presented as mean ±
SD. The results were analyzed by two-way ANOVA. Differences were considered significant at
p<0.05 versus control.

2.3

Results

2.3.1 Prostate cancer cell growth and DNA synthesis were inhibited by Zyflamend®

Zyflamend® inhibited growth in all PrC cell lines tested in a time and concentrationdependent manner. At the end of 96 hr treatment, Zyflamend® inhibited cell growth in RWPE-1
cells by 80%, LNCaP cells by 60%, PC3 cells by 50% and CWR22Rv1 cells by 75% (Fig.2.1A).
To further confirm the reduction of cell proliferation by Zyflamend®, BrdU assay was used for
determining DNA synthesis during the cell cycle. After treatment with Zyflamend® (48 hr),
BrdU incorporation in CWR22Rv1 cells was reduced in a concentration-dependent manner
compared to control (Fig. 2.1B).
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2.3.2 Zyflamend®-mediated induction of cell cycle inhibitors p21 and p27, mRNA and
protein

In CWR22Rv1 cells, Zyflamend® treatment (24 hr) induced mRNA levels for the cell
cycle inhibitors p21 and p27 (Fig. 2.2A). Concomitantly, protein levels of p21 and p27 were
increased by 4-fold and 2-fold, respectively, with Zyflamend® treatment compared to controls
(Fig. 2.2B). While p21 protein expression increased in the presence of Zyflamend®, p53
expression appears to be initially down regulated but these effects did not influence p21 (Fig.
2.2C). In addition, cyclin E was down-regulated with no change in cyclin D1 expression (data
not shown). Changes in p21 protein levels were determined and relative changes in expression,
turnover, or both were investigated. In the presence of Zyflamend® (24 hr), p21 protein
expression was increased (lane 1 versus lane 2) (Fig. 2.2D). When Zyflamend® was removed
(after 24 hr exposure), p21 levels did not change (lane 2 versus lane 4); however, when
Zyflamend® was maintained for an additional 24 hr, protein level of p21 continued to increase
(lane 2 versus lane 3), indicating Zyflamend® continuously induced p21 protein synthesis and/or
prevented p21 protein degradation. To investigate p21 protein protection from degradation by
Zyflamend®, cycloheximide (an inhibitor of protein synthesis) was added to the cells after 24-hr
treatment with Zyflamend®; however, changes in p21 protein levels were not different in the
control versus Zyflamend® treated cells (Fig. 2.2E).
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A

B

Figure 2.1 The effects of Zyflamend® on cell proliferation were determined using MTT or BrdU
incorporation assays. A, RWPE-1, LNCaP, PC3 and CWR22Rv1 cells were treated
±Zyflamend® (0, 100, 150 and 200 ug/ml) over 24, 48, 72 and 96 hr. B, CWR22Rv1 cells were
treated with Zyflamend® for 48 hr prior to the BrdU incorporation assay. Data are presented as
mean ± SEM. *p<0.05, ** p<0.005.
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A

B

Figure 2.2 Effects of Zyflamend® on p21 expression using CWR22Rv1 cells. A, p21 and p27
mRNA levels (*p<0.05, ** p<0.005) were detected using qRT-PCR after 24 hr Zyflamend®
treatment. B, p21 and p27 protein levels (24 hr treatment of Zyflamend®) using immunoblotting.
C, protein levels of p21, p53, and cyclin E. D, p21 levels were detected in cells treated
±Zyflamend® after 24 hrs (lane 1: control; lane 2: +Zyflamend®); after 24 hr Zyflamend®
treatment, cells were treated ±Zyflamend® for another 24 hr (lane 3: +Zyflamend®; lane 4: Zyflamend®). E, CWR22Rv1 cells were treated with Zyflamend® for 24 hr prior to adding
cycloheximide. Cells were then treated ±Zyflamend® for another 0-4 hr.
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E

Figure 2.2 Continued.
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2.3.3 p21 silencing induces cell growth
To link the molecular effects with biological outcomes, changes in p21 expression with
cell growth were determined. CWR22Rv1 cells were transfected with siRNA against p21 in the
presence or absence of Zyflamend®. Zyflamend® increased p21 mRNA expression in mock
(p<0.005) and in negative control siRNA transfections (p<0.05) (Fig. 2.3A) with concomitant
reductions in cell number (Fig. 2.3B). Transfection of p21 siRNA reduced p21 mRNA in the
absence or presence of Zyflamend® (Fig. 2.3A). Comparing the mock/negative control groups to
the p21 siRNA group in the presence of Zyflamend® (closed bars), there was a reduction in p21
mRNA levels with p21 siRNA treatment (Fig. 2.3A) and a concomitant increase in cell number
(Fig. 2.3B). However, in cells not treated with Zyflamend® (open bars), cell numbers did not
change following p21 siRNA treatment (Fig. 2.3B) despite reduced p21 expression below the
baseline.
2.3.4 p21 overexpression reduced cell growth
To mimic the effect of Zyflamend®-induced p21, p21was overexpressed in CWR22Rv1 cells
and confirmed by western blot (Fig. 2.3C). p21 protein levels were increased in cells with the
p21 overexpression construct (lane 3) and in the presence of Zyflamend® (lane 2). The
expression of p21 was further enhanced in the p21 stably transfected cells with the additon of
Zyflamed® (lane 4). Both p21 overexpression and the presence of Zyflamend® reduced cell
proliferation over time (p<0.0005). The reduction of cell proliferation by p21 overexpression was
potentiated in the presence of Zyflamend® (p<0.00005, Fig 2.3D). These results were supported,
in part, by the fact that Zyflamend® increases p21 promoter activity (data not shown) using a full
length human p21 promoter (2.4kb) luciferase reporter construct, consistent with increases in
mRNA and protein levels.
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A

B

Figure 2.3 Effects of p21 on cell growth ±Zyflamend® using p21 silencing and p21
overexpression. A, p21 mRNA levels, and B, cell proliferation, were determined in the presence
or absence of Zyflamend® (24 or 96 hrs, respectively) in cells transfected with mock (reagent
only), negative (scramble SiRNA) and p21 SiRNA. Data are presented as the mean ± SD.
C, p21 protein levels in cells transfected with vector or pRc/CMV-p21 treated ±Zyflamend® for
24 hr. D, Effects of Zyflamend® on cell proliferation in p21 or vector stably transfected cells
using MTT assay. Data are presented as the mean ± SEM. *p<0.05, **p<0.005, †p<0.0005,
‡p<0.00005 and §p<0.000005.
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Figure 2.3 Continued.
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2.3.5 p21 overexpression associated with cell growth reduction was significantly
enhanced by Zyflamend®, but not individual herbs

Of interest was whether any of the individual herbal extracts had the same effect as the
combined herbal extracts (i.e., Zyflamend®) (Fig. 2.4). We evaluated the effects of each herbal
extract on p21 mRNA expression and cell proliferation using the same concentrations found in
Zyflamend®. Individual herbal extracts or Zyflamend® were added to CWR22Rv1 cells for 24
and 48 hrs. Extracts of five herbs (barberry, goldthread, skullcap, green tea and ginger)
significantly reduced p21 mRNA levels and three herbs (turmeric, hu zang and holy basil)
significantly increased p21 mRNA levels; the extract from rosemery had no effect on p21 mRNA
expression. Nevertheless, Zyflamend® had the most robust effect on increasing p21 mRNA
levels (p=0.0004) (Fig. 2.4A) and was the only treatment that reduce cell proliferation (Fig.
2.4B).

2.3.6 Zyflamend®-mediates inhibition of HDACs

Because regulation of p21 expression has been linked to HDAC activity, the effects of
Zyflamend® on class I and class II HDACs were investigated using CWR22Rv1 cells. In the
presence of Zyflamend®, mRNA expression of all HDACs tested (HDAC1-7) was reduced by
30-80% (Fig. 2.5A). The reduction of HDAC protein levels was confirmed by western blot, and
treatment with TSA (general HDAC inhibitor) was used as a control (Fig. 2.5B). Zyflamend®
reduced protein levels (i.e., lane 1 versus lane 5) for HDAC1, HDAC2, HDAC3, and HDAC4,
but not with HDAC5 or HDAC7. Treatment of CWR22Rv1 cells with TSA was shown to inhibit
HDAC3 and HDAC4 expression in a dose-dependent manner (Fig. 2.5B). Concomitantly,
Zyflamend® inhibited overall HDAC activity (nuclear extracts) (Fig. 2.5C). Since HDACs
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affect the structure of chromatin by removing acetyl groups from histones, thereby reducing
transcriptional expression, histone acetylation was examined. Histone 3 acetylation was
increased in the presence of TSA, Zyflamend® and the combination of TSA plus Zyflamend®
(lane 1, lane 5 and lane 8) (Fig. 2.5D). Induction of p21 protein expression accompanied these
changes, suggesting coordinated modulation of both events.

In addition, the effects of individual herbal extracts on HDAC expression were explored
(Fig. 2.5E). Only Chinese goldthread and baikal skullcap appeared to mimic the down-regulation
observed with Zyflamend® with regards to all HDACs tested. Extracts of rosemary, hu zang,
holy basil, turmeric, green tea, barberry and ginger were unable to duplicate the effects observed
with Zyflamend®.

2.3.7 Zyflamend®-induced p21 expression and induction of acetyl CBP/p300 via the
MAPK pathway

To determine the involvement of mitogen-activated protein (MAP) kinases on p21
protein expression, we used the Erk inhibitor U0126 ± Zyflamend®. U0126 reduced
Zyflamend®-induced p21expression (Fig. 2.6A). One target of particular interest was CBP/p300,
transcriptional coactivators with histone acetyl transferase activity, and the down-stream target
proteins of Erk and Elk-1. Zyflamend® increased the levels of phosphorylated Erk and Elk-1,
and acetylated CBP/p300 (Fig. 2.6B) in a time-dependent manner.
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A

B

Figure 2.4 Effects of individual herbal extracts versus Zyflamend® on p21 mRNA expression
and cell proliferation using CWR22Rv1 cells. A, Cells were treated with Zyflamend® or
individual herbs at doses equivalent to those in Zyflamend® for 24 hr, and p21 mRNA was
quantified by RT-PCR and normalized to control (* p<0.05). B, Cells were treated with
Zyflamend® or individual herbal extracts for 48 hr and cell proliferation was measured by MTT
assay (* p<0.05).
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D

Figure 2.5 Class I and class II histone deacetylases mRNA, protein and activity were determined
±Zyflamend® in CWR22Rv1 cells. A, HDACs mRNA levels after treatment with Zyflamend®
for 24 hr. B, HDAC proteins levels ±Zyflamend®, ±TSA after 24 hr treatment. C, Effects of
Zyflamend® on nuclear HDAC activity (nM/min/ug protein). D, Acetyl histone 3 (AcH3),
histone 3 and p21 protein levels ±Zyflamend®, ±TSA after 24 hr. E. Effects of individual herbal
extracts on mRNA levels of various histone deacetylases.
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E

Figure 2.5 Continued.
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A

B

Figure 2.6 Effects of Zyflamend® on the mitogen-activated protein kinase (MAPK) pathway and
p21 expression. A, Effect of Zyflamend® on p21 protein expression in the presence or absence
of the Erk inbibitor U0126 (2 uM). B, Effects of Zyflamend® (0-60 min treatment) on protein
expression of p-Erk, p-Elk-1 and acetyl-CBP/p300. C. A model of epigenetic regulation by
Zyflamend® on p21 expression by activation of histone acetyl transferase (CBP/p300) through
MAPK pathway and inhibition of histone deacetylases reducing cell proliferation.
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Figure 2.6 Continued.
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2.4

Discussion

The use of herbs and botanicals and their bioactive components are effective inhibiting
growth, angiogenesis, metastasis and inducing apoptosis in many tumor lines. Many of their
molecular mechanisms of action have been characterized in vitro (12, 5, 13). In addition, the use
of herbal extracts in combination appears to potentiate each other‟s actions, resulting in
significant activity whereas single agents may have greatly reduced effects (7, 14).

Zyflamend® is derived from the extracts of ten different herbs, each with reported
medicinal properties. Individuals diagnosed with HGPIN are at increased risk for developing PrC
(15). When this polyherbal preparation was used in a Phase I clinical trial with patients
diagnosed with HGPIN, reductions in PSA and re-diagnosis to benign forms of prostate tissue
were reported (8, 16). Based on this data, we investigated the effects of Zyflamend® in a cell
model of castrate-resistant PrC with a particular interest in identifying molecular mechanisms of
action.

To understand the doses used in this study, we chose a maximum dose of Zyflamend®
based on the levels of curcumoids (~7% w/w in turmeric (17)) found in the poly-mixture. This
level of curcumoids would be equivalent to the identifiable range of human plasma
concentrations for Zyflamend® at these physiologically relevant concentrations inhibited PrC
cell growth in concentration- and time-dependent manners. These effects were observed in
RWPE-1 cells (immortalized prostate epithelial cells that represent an early stage of the disease,
i.e., PIN (18)), and in tumor cell lines representing androgen-dependent (LNCaP), androgenindependent (PC3), and castrate-resistant (CWR22Rv1) forms of the disease. Similar results with
Zyflamend® were observed by others using PC3 and LNCaP cell lines (9, 11). Because of our
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previous interest of investigating castrate-resistant PrC (19), we focused our attention on those
underlying molecular mechanisms responsible for these effects using CWR22Rv1 cells.

Zyflamend® increased cell cycle regulators p21 and p27, duplicating previous results of
Zyflamend® on p21 expression (9, 11). P21 and p27 are common targets for bioactive
phytonutrients (7, 20). Zyflamend® consistently enhanced mRNA and protein levels in doseand time-dependent manners. These effects were always biologically correlated with reductions
in cell proliferation. Increases in p21 protein levels were due to increases in transcription and not
a reduction in protein stability. Transcriptional expression of p21 can be regulated by p53dependent (21-23) and/or p53-independent (24-31) mechanisms. We observed that Zyflamend®mediated increases in p21 were not accompanied by concomitant changes in p53 expression. We
also observed reductions in the expression of cyclin E, a protein inhibited by p21 and involved in
regulating the transition of the G1/S phase of the cell cycle. In addition to these effects,
Zyflamend® has been reported to modify other cell cycle regulators, including retinoblastoma
protein (phosphorylation) and cyclin D1 in PC3 cells (11).

To confirm that Zyflamend® was attenuating cell proliferation, in part, by up-regulating
p21 expression, we used siRNA technology to silence p21 and stably transfected cells for over
expression. Overexpression of p21 significantly inhibited proliferation, duplicating those effects
observed with Zyflamend®. Knocking down p21 mRNA levels in the absence of Zyflamend®
had no effect on cell proliferation, suggesting the basal level of p21 was not acting in a
regulatory manner. However, knocking down Zyflamend®-induced p21 mRNA levels increased
cell proliferation, reaffirming that the effects of Zyflamend® are, in part, mediated by p21
upregulation. Importantly, when Zyflamend® was added to cells overexpressing p21, there was
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an added reduction in cell proliferation, suggesting multiple mechanisms may be involved. This
makes sense since Zyflamend® is comprised of 10 different herbal extracts.

Induction of p21 expression by the individual herbal extracts was quite variable.
However, cell proliferation was unaffected by any of the herbal extracts when used individually
at concentrations present in the Zyflamend® preparation; only the combination proved to be
effective. Levels of each extract when used individually could have been below the
physiologically active threshold, accounting for the lack of effects on cell proliferation (as
discussed in Ref (5)).

Post-translational modification of histones, in particular the removal or addition of acetyl
groups on ε-N-acetyl lysine residues, play an important role in epigenetic regulation of
transcription (32). Acetylation of the N-terminal tails of histones “relaxes” the chromatin making
it more accessible for binding by coactivating factors. The result is an increase in gene
expression. In contrast, deacetylation results in a more compact chromatin and transcriptional
repression. Regulation of acetylation is a balance between histone acetyl transferases and histone
deacetylases (HDACs) (33). HDACs in particular are important in cancer biology, by promoting
proliferation, angiogenesis, migration/metastasis, resistance to chemotherapy, and inhibiting
apoptosis and differentiation (as reviewed in Ref (34)). Identification of HDAC inhibitors is
therefore a new therapeutic approach to treat cancer (35).

Epigenetic regulation via acetylation is important in regulating tumor suppressor genes,
such as p21 (36). Zyflamend® increased acetylation of histone 3, in part, by down regulating
mRNA levels of class I and class II HDACs (HDAC1-7), reducing protein expression of HDAC1,
HDAC2 and HDAC4, and inhibiting HDAC activity. HDAC1 and HDAC4 have been shown to
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be particularly specific for the repression of p21 expression (37, 36, 38). Hyper-acetylation of
Sp1 binding sites in the proximal promoter is a key regulator of p21 expression (36) and HDAC4
has been shown to regulate expression through a Sp1-dependent, p53-independent pathway (37).

In contrast to Zyflamend®, when cells were treated with the individual herbs, only
goldthread and skullcap reduced HDAC expression, but interestingly p21 expression was down
regulated in the presence of either of these herbal extracts. There is increasing evidence that
many bioactive phytochemicals may function as histone deacetylases inhibitors, but these results
typically are generated with concentrations many times higher than what was used here (39).

Up regulation of p21 expression also is coordinately regulated by CBP/p300. CBP/p300
proteins are transcriptional coactivators with histone acetyltransferase activity that is involved in
the regulation of p21 expression through the Sp1 binding sites (40-41). The histone
acetyltransferase activity of CBP/p300 is increased by phosphorylation and is regulated upstream
by Erk-1/-2 and its downstream regulator, Elk-1 (42). MAP kinase-dependent phosphorylation of
Elk-1 results in interaction with p300 and increased histone acetyltransferase activity (43). In a
time-dependent manner, Zyflamend® increased the expression of pErk and pElk-1, followed by
the acetylated form of CBP/p300 (44). MAP kinase involvement was confirmed using the Erk1/-2 inhibitor U0126 which resulted in the down regulation of pErk in a time dependent manner
(data not shown) and inhibition of Zyflamend®-induced p21 expression. Stimulation of p21
expression via up regulation of the Erk pathway has been observed by others and these effects
were similarly blocked in the presence of the Erk-1/-2 inhibitor U0126 (45).
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In summary, Zyflamend® is composed of ten concentrated herbal extracts. It has been
used successfully in a Phase I clinical trial (8), suggesting it may be helpful for patients
diagnosed with PIN, which is related to development of PrC. These studies suggest it also may
have utility in addressing advanced forms of PrC. The concentrations used in this study were of
importance and carefully considered. When compared to the multi-herbal preparation, the use of
the herbal extracts in isolation could not duplicate the overall effects of Zyflamend®, and this
may be related to those concentrations used. Zyflamend inhibited tumor cell growth in vitro, in
part, by up-regulating the tumor suppressor protein p21. The epigenetic regulation of p21 by
Zyflamend® can be summarized in Figure 2.6 C. Increased expression of p21 was coordinately
regulated by activation of the histone acetyltransferase CBP/p300 through up regulation of pErk
signaling and through concomitant down regulation of class I and class II HDACs. These effects
modified histone hyper-acetylation, a key activator of p21 expression and cell cycle regulation.
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Chapter III
Zyflamend® Reduces the Expression of Androgen Receptor and
Insulin-Like Growth Factor Receptor, Biomarkers of Cancer
Relapse, in a Model of Castrate-Resistant Prostate Cancer
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Abstract
Prostate cancer is the most commonly diagnosed solid malignancy and tumor cells
eventually transform to castrate-resistant or androgen-independent relapse through the proposed
activation of the androgen receptor via insulin-like growth factor receptor (IGF-1R) signaling
involving phospho-AKT (pAKT). In this study, a mixture of medicinal herbal extracts,
Zyflamend®, was used as an adjuvant treatment in a model of castrate-resistant prostate cancer,
CWR22Rv1 cells. We found that Zyflamend® reduced androgen receptor and IGF-1R
expression along with a reduction of IGF-1-mediated proliferation of CWR22Rv1 cells. To
investigate the involvement of pAKT in the downstream signaling of IGF-1, IGF-1 activated
AKT phosphorylation; however, the induction of pAKT was not associated with androgen
receptor expression. Further, constitutive active form of AKT had no effect on nuclear expression
of androgen receptor, indicating that upregulation of pAKT did not promote androgen receptor
expression or nuclear translocation in castrate-resistant CWR22Rv1 cells. Conversely,
Zyflamend® reduced androgen receptor expression following IGF-1 stimulation and in cells
over-expressing pAKT. These results demonstrated that Zyflamend® inhibited IGF-1-stimulated
cell growth, IGF-1R expression and androgen receptor expression and its nuclear localization,
but these effects were not mediated through PI3K/pAKT signaling. In addition to an inhibition of
androgen receptor and its growth promoting effects by Zyflamend®, it was found that
Zyflamend® influenced indices of proliferation and apoptosis by inducing caspase 3 activity,
PARP cleavage, and inhibiting Bcl-2 expression and the proliferative biomarker Ki67. In
conclusion, Zyflamend® inhibited IGF-1R and androgen receptor expression in a PI3K/pAKT
independent manner. Furthermore, some of Zyflamend‟s effects involve a concomitant decrease
in cell proliferation and an increase in programmed cell death.
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3.1. Introduction
Prostate cancer is the most commonly diagnosed solid malignancy. In the last few years,
prostate cancer has become the second leading cause of cancer-related deaths in men in the
United States (1-2). The advanced forms of prostate cancer metastasize to distant organs, most
commonly bone, and eventually become castrate-resistant or androgen-independent following
androgen deprivation (commonly referred to as androgen deprivation or hormone ablation
therapy) (3). This advanced stage of the disease is very difficult to treat and is invariably fatal.

Zyflamend® is a poly herbal preparation consisting of the supercritical CO2 fluid extracts
of ten different medicinal herbs shown to have anti-neoplastic activity. In phase I clinical trials,
Zyflamend® has demonstrated efficacy in patients with high-grade prostatic intraepithelial
neoplasia (HG-PIN), a premalignant form of the disease (4), and has inhibited the growth of
androgen-dependent, androgen-independent and castrate-resistant prostate cancer cells in vitro
and in vivo via multiple mechanisms (5-6). These latter results suggest that Zyflamend® could
potentially have efficacy in metastatic forms of this disease, a possible adjuvant to hormone
deprivation therapy. The mechanisms of prostate cancer cell resistance to androgen
withdrawal have been investigated and one mechanism that is repeatedly mentioned as a
potential target is reactivation of androgen signaling in the absence of androgens (7).
Amplification of androgen receptor expression (8) and activation of androgen signaling, in
the absence or presence of very low levels of androgens, may involve crosstalk with other
signaling pathways (9-10). For example, androgen receptor signaling can be activated via
crosstalk between, insulin-like growth factor-1 (IGF-1)/ insulin-like growth factor-1 receptor
(IGF-1R) signaling. Levels of IGF-1 are significantly higher in metastatic prostate cancer
patients when compared with the controls (11) and IGF-1/IGF-1R signaling have been shown to
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activate the androgen receptor in the presence of low levels of androgens (12).Similarly, the
expression of IGF-1R is increased in patients with progressive forms of prostatic neoplasia (13),
demonstrating a correlation of IGF-1/IGF-1R and prostate cancer progression. The mechanisms
of IGF-1/IGF-1R on androgen receptor activation have linked IGF-1/IGF-1R signaling to
increased androgen receptor activity through phosphatidylinositol 3-kinase (PI3K)/AKT
phosphorylation (12, 14). The PI3K/AKT pathway is reported to activate androgen receptor
signaling via the dissociation of a suppressor-androgen receptor complex, thus allowing
androgen receptor to bind to the promoter regions of target genes such as prostate specific
antigen (PSA) (15-16) and cell proliferative promoting growth factors such as IGF-1 (17),
forming a positive feedback of androgen receptor and IGF-1 signaling. However, this pathway
has yet to be studied in a model of castrate-resistant prostate cancer using cells that are more inline with the human disease, those that express an active androgen receptor, secrete human PSA
and can grow in an androgen-deprived environment.

In this study, we used a combination of herbal extracts, Zyflamend®, as an adjuvant
therapy in an experimental model of castrate-resistance using a the human prostate cancer cell
line, CWR22Rv1. Zyflamend® has been found to inhibit androgen receptor expression in an
androgen-dependent prostate cancer cell line, LNCaP (5), but the mechanisms were not
investigated. In this study, we found that Zyflamend® reduced protein levels of IGF-1R and
androgen receptor in CWR22Rv1 cells and investigated whether crosstalk between these
pathways involved PI3K/AKT signaling.
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3.2. Materials and Methods
3.2.1 Cell Culture
Human prostate cancer cell line, CWR22Rv1, was purchased from American Type
Culture Collection (Rockville, MD). CWR22Rv1 cells were maintained in RPMI 1640 media
supplemented with 10% fetal bovine serum under an atmosphere of 5% CO2 at 37oC. Cells were
harvested with the addition of 0.25% trypsin with 0.02% EDTA during the exponential growth
phase. For the experimental treatments, cells were cultured in RPMI 1640 media supplemented
with 0.05% fetal bovine serum containing Zyflamend® ( New Chapter, Inc, Brattleboro, VT)
reconstituted in dimethyl sulfoxide (DMSO) for cell proliferation assay, mRNA extraction and
protein isolation. In all experiments, 0.1% DMSO was used as the vehicle control. CWR22Rv1
cells are hormone independent and represent a very late stage of prostate cancer following
hormone ablation. On the other hand, CWR22Rv1 cells produce PSA and express a functional
androgen receptor. These cells can grow in the presence or absence of androgens and are
considered to be a castrate-resistant cell line (18). CWR22Rv1 cells were chosen for most of the
experiments because prostate cancer cells in most patients who relapse following androgen
ablation therapy express androgen receptor and produce PSA.

3.2.2 Cell Proliferation
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] (Andwin
Scientific, Addison, IL) is cleaved by metabolically active cells to form a formazan,
chromaphore product that absorbs at 540 nm. The MTT assay was used to assess relative cell
growth and viability, following the manufacturer‟s instructions (Promega, Madison, WI). Cells
(1×104 cells of CWR22Rv1) were plated in 96-well plates in a volume of 100 ul culture medium.
The culture medium contained 200 ug/ml of Zyflamend® in the presence or absence of insulin
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growth-like factor-1 (100 ng/ ml). 0.1% of DMSO was used as the controls. For PI3K inhibitor
experiments, cells were treated wortmannin (1.0 μM). Cell proliferation was determined at 0, 24,
48, 72, 96 hr post incubation. At each time point, a mixture of MTT:complete medium (1:10,
v/v) was added and incubated at 37 oC for 4 hr in a CO2 incubator (5%). The absorbance was
measured on a SpectraCount microplate photometer (Perkin Elmer Inc, Waltham, MA).

3.2.3 Induction of pAKT by Adenovirus infection
CWR22Rv1 cells (1.5×105 cells per well in 6-well plates) were plated overnight prior to
adenovirus infection. The myrAkt1 adenovirus N-terminally myristoylation signal-attached Akt
(myr-Akt) expresses constitutive active AKT1 protein described previously (19). CWR22Rv1
cells in RPMI 1640 media containing 10% FBS were infected with the myrAKT1 adenovirus
for 6 hr, after which time the cells were cultured overnight in RPMI 1640 media containing
0.5% FBS while β-Gal constructed adenovirus was used as the control. Infected cells were pretreated with vehicle or Zyflamend® (200 ug/ml) for 24 hr at 37 oC. Protein expression of
pAKT (serine 473), AKT and androgen receptor was examined by western blot.

3.2.4 Western blotting
CWR22Rv1 cells were lysed in the presence of cell lysis buffer (Cell Signaling
Technology®, Inc. Danver, MA). Protein concentrations of the lysates were quantified by BCA
protein assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (15 ug) were fractioned by
8~12% SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by
electroblotting. The membranes were blocked using 5% nonfat dry milk in 0.1% Tris buffered
saline-Tween-20 (TBST) for 1 hour and were incubated with primary antibodies overnight at 4°C.
The membrane was incubated with anti-mouse or anti-rabbit secondary antibody conjugated with
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horseadish peroxidase (HRP) (Cell Signaling Technology®, Inc. Danver, MA). Protein
expression was detected with a Pierce ECL Western Blotting detection system. Each membrane
was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ). Antibodies of AR, phosphoser473-AKT, AKT, cleaved caspase 3, poly (ADP-ribose) polymerase, p65 (Cell Signaling
Technology®, Inc. Danver, MA), IGF-1Rα and Ki67 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) were used. β-actin with anti-β-actin antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was used as the control.

3.2.5 Immunofluorescence staining
CWR22Rv1 cells were seeded on the cover slips supplemented in RPMI 1640 media with
10% FBS under an atmosphere of 5% CO2 at 37oC overnight. Before the treatment, CWR22Rv1
cells were maintained in RPMI 1640 media with 0.5% FBS. For the observation of androgen
receptor translocation, the cells were pretreated with Zyflamend® (200 ug/ml) for 24 hr. After
the treatment, the cells were fixed using 2% paraformaldehyde for 15 min, followed by blocking
with 10% goat serum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1hr, and antiandrogen receptor antibody (1 μg) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at
4 oC. Alexa Fluor® 488 goat anti-rabbit IgG was used as secondary antibody.

3.2.6 Caspase 3/7 activity assay
CWR22Rv1 cells were lysed in cell lysis buffer after treated with Zyflamend®. Fifty μg
of cell lysates were used for the Caspase 3/7 Assay (Promega, Madison, WI). Briefly, 50 μg of
cell lysates in 50 μl lysis buffer were mixed with 50 μl of caspase 3/7 reagent and incubated in
dark for 1 hr at room temperature. Caspase 3/7 activity was measured on a FluoroCount
microplate photometer (Perkin Elmer Inc, Waltham, MA) at a 485 nm excitation and a 527 nm
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emission.

3.2.7 Protein degradation
CWR22Rv1 cells were cultured with RPMI 1640 medium containing Zyflamend® (200
μg/ml) for 24 hr prior to adding cycloheximide (10 μM) to terminate protein synthesis for an
additional 0, 0.5, 1, 1.5, 2, 4 hr in the continued presence or absence of Zyflamend® (200 μg/ml)
and harvested for protein analysis.
3.2.8 RNA isolation and quantitative RT-PCR
Total RNA was isolated from CWR22Rv1 cells using Trizol reagent (Invitrogen,
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100%
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water.
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc.
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™
(Thermo Scientific Wilmington, DE). Total RNA (2 μg) from each sample was mixed with
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System,
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR
amplification with primer sets (2.5 μM) of androgen receptor sense, 5‟CCTGGCTTCCGCAACTTACAC-3‟ and antisense 5‟- GGACTTGTGCATGCGGTACTCA-3‟,
and prostatic specific antigen sense, 5‟ - ACCAGAGGAGTTCTTGACCCCAAA-3‟ and
antisense 5‟- CCCCAGAATCACCCGAGCAG-3‟ were examined. Amplification was performed
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using a standard thermocycle program beginning with an initial temperature at 94°C for 1 min
followed by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was
examined in triplicate and the amounts of PCR product were normalized with 36B4, 5‟TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as the
internal control.

3.2.9 Statistical analysis
The results are presented as mean ± SD and multiple comparisons are analyzed by a twoway ANOVA. Differences were considered significant at p<0.05.

3.3. Result
3.3.1 Effect of Zyflamend® on the growth of castrate-resistant prostate cancer
CWR22Rv1 cells

Zyflamend® inhibited growth of castrate-resistant prostate cancer cells, CWR22Rv1 cells,
in a time-dependent manner. After 48 hr treatment, Zyflamend® significantly inhibited cell
growth by 38% (p<0.005), and cell growth was further reduced by 70% (p<0.005) after a 96 hr
treatment (Figure 3.1).

3.3.2 Zyflamend® and androgen receptor and prostate specific antigen expression

Androgen receptor in CWR22Rv1 cells was detected via immunofluorescent imaging
following 24 hr treatment of Zyflamend®. The green fluorescent stain corresponds to protein
intensity. Zyflamend® reduced androgen receptor intensity as measured via immunofluorescent
staining (Figure 3.2A). This result was confirmed with western blot analysis (Figure 3.2A).
Concomitantly, androgen receptor and prostate specific antigen mRNA levels were decreased by
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greater than 65%. However, androgen receptor degradation was not promoted by Zyflamend®
(Figure 3.2 C) when protein synthesis was blocked by cycloheximide.

3.3.3 Zyflamend® and its effect on cell proliferation in the presence or absence of
IGF-1

CWR22Rv1 cells were treated with IGF-1 (10 and 100 ng/ml) with and without
Zyflamend® (200 µg/ml) for up to 96 hrs. IGF-1 increased cell proliferation in a dose-dependent
manner and these effects were significantly attenuated in the presence of Zyflamend® (Figure
3.3B). These results were consistent with a reduction in the protein levels of IGF-1R (Figure
3.3C). Cultured cell morphology was monitored over 96 hr following treatment with vehicle
(control), IGF-1, Zyflamend® and a combination of IGF-1 and Zyflamend® (Figure 3.3D).
IGF-1 increased cell density compared to the control cells after 24 hr treatment. Conversely,
cells started to shrink, round-up, and detach with treatment of Zyflamend® at 24 hr compared to
the control and IGF-1-treated cells (Figure 3.3E). This affect of Zyflamend® was delayed by
IGF-1, but by 48 hr cells exposed to the combination of IGF-1 and Zyflamend® were similar to
Zyflamend® alone. After 96 hr IGF-1 co-treatment had no observable affect in combination
with Zyflamend®.
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Figure 3.1 The effect of Zyflamend on cell proliferation. CWR22Rv1 cells were treated with
Zyflamend® (200 μg/ ml) for 0-96 hr and cell proliferation was compared to control using MTT
assay. Values are means±SEM (n=8/group). Differences were considered significant at p<0.05 as
compared to control.
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A

Figure 3.2 Effect of Zyflamend® on androgen receptor (AR) and prostate specific antigen (PSA)
expression. A. Zyflamend® (200 μg/ml) was added to the cells for 24 hr and the expression of
AR was detected using immunofluorescent staining and protein expression via western blot
analysis. B. Expression of mRNA levels of AR and PSA were detected using RT-PCR following
24 hr-treatment of Zyflamend® (200 μg/ml). Values are means±SEM (n=3/group) and
considered significant at p<0.05 as compared to the control. C. AR synthesis was blocked using
cycloheximide for 4 hrs with or without Zyflamend® and levels of AR were monitored via
western blot analysis.
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Figure 3.2 Continued.
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Figure 3.3 Effect of Zyflamend® on IGF-1R expression and cell proliferation in the presence or
absence of IGF-1. A. This figure presents the signaling model where IGF-1/IGF-1R potentially
promotes cell growth via pathways dependent upon or independent of androgen receptor. B. Cell
proliferation (0-96 hr) in the presence or absence of IGF-1 (10 and 100 ng/ml) and Zyflamend
(200 μg/ml). Values are means±SEM (n=8/group) and considered significant at p<0.05 as
compared to control. C. IGF-1R expression levels (protein) following 24 hr treatment of
Zyflamend® (200µg/ml). D. Effect of IGF-1 on morphological changes in CWR22Rv1 cells in
the presence or absence of Zyflamend® after treatment for 96 hrs. E. Enlarged images of
CWR22Rv1 cells following 24hr treatment of vehicle or Zyflamend® in the presence or absence
of IGF-1.
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Figure 3.3 Continued.
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Figure 3.3 Continued.
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3.3.4 Effect of IGF-1 and Zyflamend® on pAKT, IGF-1R and androgen receptor
expression

To investigate whether IGF-1/IGF-1R signaling regulates androgen receptor expression
and/or nuclear translocation via pAKT, CWR22Rv1 cells were treated with IGF-1 (10 and 100
ng /ml) for 10 min to stimulate AKT phosphorylation (Figure 3.4 A). To determine if these
effects influenced the expression of IGF-1R and androgen receptor in the presence or absence of
Zyflamend®, cells were pre-treated with IGF-1 (100 ng/ml) for 10 min, followed by treatment of
±Zyflamend® for up to 24 hr. As demonstrated previously, pre-treatment of cells with of IGF-1
increased pAKT expression, with no effect on IGF-1R and androgen receptor expression.
Zyflamend®, on the other hand, reduced IGR-1R receptor expression (as reported previously),
but increased phosphorylation levels at serine 473 on AKT were not associated with an induction
ofandrogen receptor expression. These results question the link between pAKT and androgen
receptor expression (Figure 3.4B).

To confirm that IGF-1/IGF-1R signaling was not influencing androgen receptor
expression and nuclear translocation, cells were pretreated in the absence or presence of IGF-1
(100 ng/ml, 10 min) followed by Zyflamend® (200 ng/ml) for 24 hr and the levels of androgen
receptor (cytosol and nucleus) were determined via immuno-fluorescent staining (Figure 3.4 C).
Cellular and nuclear levels of androgen receptor were unaffected by preincubating cells with
IGF-1, suggesting that IGF-1 signaling did not affect nuclear translocation. On the other hand,
Zyflamend® reduced cellular and nuclear levels of androgen receptor independent of IGF-1.
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A

B

Figure 3.4 Effect of IGF-1 and Zyflamend® on pAKT, IGF-1R and androgen receptor (AR)
expression. A. Effect of IGF-1 (10 and 100 ng/ml) on expression levels of pAKT. B. Effect of
IGF-1 (pretreatment of 100 ng/ml for 10 min) in the presence or absence of Zyflamend® (0-24
hr). IGF-1Rα, AR, AKT and phospho-ser473 AKT were valued using immunebloting. C.
CWR22Rv1 cells were treated with Zyflamend for 24 hr prior to treatment with IGF-1 (100
ng/ml). Expression of AR was evaluated using immuno-fluorescent staining. Nuclear AR
intensity was quantified with DAPI staining. Values are means±SEM (n=250/group) and
considered significant at p<0.05 as compared to control.
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C

Figure 3.4 Continued.

142

3.3.5 Effect of overexpression of pAKT via adenovirus infection on androgen receptor
expression and translocation

To investigate the effect of AKT phosphorylation on androgen receptor expression and
nuclear translocation, overexpression of pAKT via myrAkt1 adenovirus was used. Increasing the
levels of the adenovirus resulted in increased levels of AKT and pAKT, but had no effect on
androgen receptor expression (Figure 3.5A). Zyflamend® treatment of adenovirus-infected cells
inhibited androgen receptor expression and these results were not associated with pAKT levels.
These results suggest that although Zyflamend® reduces the expression of androgen receptor
(cellular and nuclear) and IGF-1R, these effects are not mediated via changes in pAKT.

3.3.6 Inhibition of PI3 kinase with wortmannin in the presence or absence of
Zyflamend®
Wortmannin (1.0 µM), a PI3 kinase inhibitor, and Zyflamend® (200 ug/ml) inhibited cell
proliferation in a time dependent manner. Wortmannin reduced cell growth by 57% after 96 hr
treatment (Figure 3.6A). LY294002, another PI3 kinase inhibitor, showed the same reductions in
cell growth over the time period (data not shown), indicating PI3K inhibition reduces
CWR22Rv1 cell growth and these effects were similar to or greater than those observed with
Zyflamend® (Figure 3.6B). . However, the inhibitory effect of wortmannin on the PI3 kinase
pathway did not reduce androgen receptor expression (Figure 3.6 C).

3.3.7 Effects of Zyflamend® on biomarkers of apoptosis and proliferation
Zyflamend® (200 ug/ml) reduced the levels of pro-caspase 3 in a dose-dependent manner
(Figure 3.7 A) and concomitantly increased caspase 3 activity (Figure 3.7 B). Cleavage of PARP,
a downstream target of caspase 3, was increased in the presence of Zyflamend® (Figure 3.7 C).
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Expression of the proliferative marker, Ki67 and the anti-apoptotic protein, Bcl-2, were inhibited
by Zyflamend® treatment (Figure 3.7 C), suggesting Zyflamend® affects tumor cell number by
coordinately increasing apoptosis and inhibiting cell proliferation.
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A

Adeno-AKT

B

Adeno-AKT

Figure 3.5 Androgen receptor expressions in CWR22Rv1 cells infected with the adenovirus
myrAKT1 in the absence or presence of Zyflamend®. A. CWR22Rv1 cells were infected with
adeno-myrAKT1 at uncreasing doses while β-Gal was used as the control. Total AKT, phosphoserine473-AKT, androgen receptor and β-actin were detected via western blot analysis. B.
Androgen receptor levels in the nuclear fraction of CWR22Rv1 cells following infection with
adeno-myrAKT1. C. Protein expression of androgen receptor and pAKT in CWR22Rv1 cells coincubated with adeno-myrAKT1 and Zyflamend® (200 ug/ml).
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C

Figure 3.5 Continued.
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Figure 3.6 Effect of Zyflamend® (200 μg/ ml) and the PI3K inhibitor, wortmannin (1.0 μM), on
cell proliferation and the expressions of pAKT and androgen receptor. Values are means±SEM
(n=8/group) and considered significant at p<0.05 as compared to control. A. CWR22Rv1 cells
were treated with Zyflamend® or the PI3K inhibitor, wortmannin and cell proliferation was
evaluated from 0-96 hr. Values are mean±SEM (n=8/group) and groups are considered
significant at p<0.0 5. B and C. Protein expressions of pAKT and androgen receptor were
determined after 48 hr treatment of Zyflamend® or wortmannin.

147

A

B

C

Figure 3.7 Effect of Zyflamend® on levels of pro-caspase-3,caspase 3/7 activity, PARP cleavage
and expressions of Bcl-2 and Ki67 in CWR22Rv1 cells. A. Protein levels of pro-caspase 3 were
determined after 24 hr treatment with Zyflamend® (0-200 ug/ml). B. Caspase3/7 activity after 24
hr treatment with Zyflamend® (200 ug/ml). Values are means±SEM (n=3/group) and considered
significant at p<0.05. C. Protein levels of cleaved PARP, Ki67, and Bcl-2 were determined after
Zyflamend® treatment (24 hr).
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3.4. Discussion

Prostate cancer relapse following androgen deprivation therapy is of particular
concern with more advanced forms of the disease, particularly in those patients with
metastatic prostate cancer. Prostate cancer cells are dependent upon androgens for growth
and androgen deprivation results in regression. However, the cancer inevitably relapses an d
up regulation of the androgen receptor is a huge concern in controlling castrate -resistant
relapse (20), as such; amplification of androgen receptor signaling has been identified as a
potential target (7, 17), where identification of compounds that can antagonize this pathway,
with few side effects, is paramount.

One of these compounds could be Zyflamend®. We previously demonstrated that
Zyflamend® can inhibit CWR22Rv1 cell proliferation via multiple mechanisms, most
notably epigenetically through histone acetylation. This study confirmed that Zyflamend®
inhibits proliferation by down-regulating the proliferative marker, Ki67 (consistent with our
earlier findings that Zyflamend® inhibited BrdU incorporation), and modifying indices of
apoptosis (increasing caspase 3 activity and PARP cleavage and reducing Bcl-2 expression).

Amplification of androgen receptor signaling includes overexpression of androgen
receptor, induction of androgen receptor activity (8), or crosstalk with other receptor pathways
such as IGF-1/IGF-1R (12, 21). Several mechanisms involving the activation of the IGF1/IGF-1R/AKT signaling pathway on androgen receptor regulation have been proposed. One
pathway involves the androgen receptor regulator Foxo1. IGF-1 activates IGF-1R and its
downstream kinases, PI3K and AKT. Activated AKT (pAKT) translocates to the nucleus and
phosphorylates Ser-253, Ser-316, and Thr-24 of Foxo1. Following phosphorylation, Foxo1
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dissociates from the androgen receptor, allowing it to activate target genes that can promote
cell growth (15). It has also been proposed that IGF-1 enhances nuclear translocation of
androgen receptor and activation of co-regulators in the absence of androgens, possibly
through the action of a variety of kinases, including AKT (17), and that transcriptional
activity of androgen receptor can be regulated by AKT-mediated phosphorylation (22). On
the other hand, there is contradictory evidence with regards to the role IGF-1/IGF-1R on
androgen receptor signaling (23).

In this study, we observed that Zyflamend® concomitantly inhibited the expressi on
of IGF-1R and androgen receptor and its nuclear translocation. Based on the reports in the
literature, it seemed logical that these effects could be coordinately mediated via the
PI3K/AKT pathway. When CWR22Rv1 cells were treated with the PI3 kinase inhibitors,
wortmannin and LY294002 inhibited cell proliferation to the same extent as Zyflamend®;
however, expression of androgen receptor was not changed.

In an effort to clarify the role of PI3K/AKT in this process, we observed that IGF-1
increased pAKT levels; however, it had no effect on androgen receptor levels, total or
nuclear, when evaluated by immuno-fluorescent staining. In contrast, Zyflamend® treatment
significantly reduced androgen receptor levels, independent of IGF-1. This regulation
appears to be at the transcriptional and translational levels as protein stability was
unaffected. Furthermore, Zyflamend® did not down-regulate pAKT despite inhibiting the
expression of IGF-1R and AR; and in fact, in some instances pAKT levels appeared to be
increased in the presence of Zyflamend®. It is possible that overexpression of pAKT could
attenuate androgen receptor expression. Alternatively, androgen receptor turnover is
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phosphorylation-dependent (involving AKT), targeting the androgen receptor for
degradation by proteasomes (24). This hypothesis seems plausible given the fact that overexpression of pAKT (by infecting CWR22Rv1 cells with the adenovirus myrAKT) was
inversely correlated with androgen receptor expression, but the levels of androgen receptor
were unaffected by wortmannin despite reducing pAKT levels, the downstream target of
PI3K. Similarly, pAKT failed to alter the levels of androgen receptor in androgen independent LNCaP-AI cells (derived from androgen-dependent LNCaP cells), or following
knocked down of AKT1 by siRNA (25).

Androgen receptor is critical to castrate-resistance/androgen-independence in more
advanced forms of prostate cancer. Mutations in the androgen receptor are associated with
castrate-resistance and appear to have gains of function that enhance the activation of androgen
receptor (26-27). CWR22Rv1 cells have two isoforms and one mutant at 874 (substitution of
tyrosine for histidine) (28), enhancing androgen receptor activity and resisting the effects of
androgen deprivation. One is a 114-kDa protein and other one is a 75~80-kDa protein. The 114kDa protein has a duplication of exon 3 encoding zinc finger domain of the androgen receptor
DNA-binding site and the truncated protein lacks the ligand-binding domain (LBD), referred to
as ARΔLBD, in COOH-terminus (18). These two isoforms don‟t exist in the parental cell line,
CWR22 cells. These two isoforms are constitutively expressed, where the smaller isoform
remains active in a hormone-deprived environment. It is possible that these changes could have
influenced how pAKT regulates and IGF-1/IGF-1R influences androgen receptor signaling.

In summary, activation of androgen receptor signaling appears to be a critical step in
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castrate-resistant relapse following hormone deprivation. It has been postulated that upregulation
of IGF-1/IGF-1R signaling contributes to this process. Zyflamend® appears to antagonize these
events by inhibiting the expression of IGF-1R and androgen receptor, resulting in significant
reductions in nuclear localization. Whether these effects are mediated, in part, by PI3K/AKT
signaling remains unclear.

152

Reference
1.

Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer

incidence and mortality. Int J Cancer. 2000;85:60-7.
2.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA

Cancer J Clin. 2008;58:71-96.
3.

Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing

hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic
carcinoma of the prostate. J Urol. 1990;144:934-41.
4.

Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Mechanisms of

disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in
the prostate. Nat Clin Pract Urol. 2007;4:321-32.
5.

Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Zyflamend, a unique

herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate
cancer cells that lack COX-2 expression. Nutr Cancer. 2005;52:202-12.
6.

Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend-

mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb
protein phosphorylation. Cancer Biol Ther. 2007;6:228-36.
7.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk

SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
N Engl J Med. 1995;332:1393-8.
8.

Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor

stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Cancer Res. 2001;61:2892-8.

153

9.

Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat

Rev Cancer. 2001;1:34-45.
10.

Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent

prostate cancer. Clin Cancer Res. 2006;12:1665-71.
11.

Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E,

Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding
proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92:1910-7.
12.

Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G,

Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth
factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-8.
13.

Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, Mayer D. Up-regulation of

insulin-like growth factor axis components in human primary prostate cancer correlates with
tumor grade. Hum Pathol. 2005;36:1186-96.
14.

Paliouras M, Diamandis EP. An AKT activity threshold regulates androgen-dependent

and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem.
2008;389:773-80.
15.

Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S,

Takayanagi R, Nawata H. Insulin-like growth factor 1/insulin signaling activates androgen
signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem.
2007;282:7329-38.
16.

Yanase T, Fan W. Modification of androgen receptor function by IGF-1 signaling

implications in the mechanism of refractory prostate carcinoma. Vitam Horm. 2009;80:649-66.
17.

Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, Bauman WA, Cardozo CP. Identification

154

of androgen response elements in the insulin-like growth factor I upstream promoter.
Endocrinology. 2007;148:2984-93.
18.

Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ.

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer
xenograft and cell line. Cancer Res. 2002;62:6606-14.
19.

Fujio Y, Guo K, Mano T, Mitsuuchi Y, Testa JR, Walsh K. Cell cycle withdrawal

promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol.
1999;19:5073-82.
20.

Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A,

Cordon-Cardo C, Costa J, Scher HI. Androgen receptor expression is associated with prostate
cancer-specific survival in castrate patients with metastatic disease. BJU Int. 2010;105:462-7.
21.

Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. Implications of insulin-like

growth factor-I for prostate cancer therapies. Int J Urol. 2009;16:161-7.
22.

Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: possible role in

androgen-independence. Curr Drug Metab. 2003;4:487-96.
23.

Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS,

Carroll JM, Roberts CT, Jr., Ware JL. Androgen receptor (AR) expression in AR-negative
prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR
activity between localized and metastatic tumors. Prostate. 2004;61:276-90.
24.

Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent

ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J.
2002;21:4037-48.
25.

Mikhailova M, Wang Y, Bedolla R, Lu XH, Kreisberg JI, Ghosh PM. AKT regulates

155

androgen receptor-dependent growth and PSA expression in prostate cancer. Adv Exp Med Biol.
2008;617:397-405.
26.

Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant

androgen receptors from human prostate cancer. Cancer Res. 2002;62:1496-502.
27.

Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a
mutated androgen receptor. Nat Med. 2000;6:703-6.
28.

McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human

prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22
tumors. Cancer Res. 2000;60:2317-22.

156

Chapter IV
Effects of a Combination of Herbal Extracts on Multiple Prostate
Cancer Xenograft Models
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Abstract
Prostate cancer (PrC) is the second deadliest cancer of males in the USA. Hormone
ablation therapy (HAT), a major therapy for metastatic forms of the disease, results in tumor
regression; unfortunately, residual cells re-grow in the absence of androgens (castrate-resistant),
and the disease is invariably fatal within 2 years. Diet is not an appropriate primary therapy
following metastasis or for refractory forms of the disease; however, diet may be effective as an
adjuvant to HAT, potentially extending the latency period and delaying relapse and/or inhibiting
refractory growth. Zyflamend® is a combination of extracts from multiple herbs, each with
reported anti-cancer properties. There is evidence that this combination is far more effective than
any herb in isolation. We and others have demonstrated that Zyflamend® can inhibit growth of
various PrC cell lines, but no studies have investigated its potential use in vivo using a model of
metastatic PrC. In this study, the inhibitory effect of Zyflamend® was examined using androgendependent and castrate resistant tumors in a mouse model that mimics the phases of this terminal
stage of the disease. At human equivalent doses, Zyflamend® potentiated the effects of HAT in
initiating tumor regression, where the time needed to reduce tumor size was almost cut in half
and the response of the tumors to intervention was less variable. Zyflamend® reduced the
expression of a number of biomarkers linked to PrC progression including pAKT, prostate
specific antigen (PSA), histone deacetylases and androgen receptor. In summary, this is the first
paper to report that a combination of herbal extracts when provided at human equivalent doses
can potentiate the effects of hormone deprivation therapy on the regression of PrC and inhibit the
growth of tumors derived from androgen-dependent and independent PrC cancer cells in vivo.
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4.1

Introduction
Prostate cancer (PrC) is the most commonly diagnosed solid malignancy and has become

the second leading cause of cancer-related deaths in men in most Western developed countries
(1). Once tumors become metastatic, they are very difficult to treat, and prognosis is poor with a
5-year survival rate of 31% (2). For the most part, PrC is temporarily responsive to hormone
deprivation therapy as prostate epithelial cells are dependent on androgens for growth.

Metastatic PrC can be divided into four distinct phases, all of which play an important
role in determining the inevitable outcome of this disease (Figure 4.1). Phase I involves initial
tumor growth following metastasis (i.e., bone). This is an androgen-dependent process
characterized by continued increases in levels of prostate specific antigen (PSA). Phase II
involves hormone ablation therapy (HAT; also referred to as hormone deprivation therapy)
followed by tumor regression (characterized by reductions in PSA levels). Although more than
95% of patients will respond to HAT and enter into a stabilization phase (Phase III), most find
their PrC will eventually relapse and become hormone refractory (Phase IV). This castrateresistant phase of the disease is invariably fatal with treatments that delay death by only a few
months. If we can delay tumor relapse, inhibit growth of androgen-dependent and refractory
tumors, and understand some of the mechanisms related to disease progression, we might be able
to increase survival time for this stage of the disease.
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Figure 4.1 The theoretical phases of metastatic prostate cancer with androgen ablation therapy
(HAT).

A preclinical experimental model mimicking this disease process has been developed
using CWR22 cells. These androgen-dependent PrC tumor cells, when used in a xenograph
mouse model, will grow into solid tumors in the presence of testosterone. These tumors will
regress following testosterone ablation and eventually relapse into a refractory cell line
(CWR22R cells) generating castrate-resistant tumors (3). CWR22Rv1 cells are a stable
immortalized cell line that is derived from the CWR22R lineage. These cells are considered
castrate-resistant because they can grow in the absence of androgens despite having a functional
androgen receptor (4). Our previous work has demonstrated that diet can potentiate the effects of
HAT and modify time-to-relapse, validating dietary intervention of the disease process using this
model (5)
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Currently, the use of medicinal herbs and their bioactive compounds have been shown to
have beneficial effects on reducing models of PrC. Combinations of herbs and bioactive
phytochemicals have been shown to be more effective than when used individually and it has
been argued that these combinations are more clinically relevant because of their synergistic
effects (6-7). Zyflamend® is one such combination. Zyflamend®, a polyherbal preparation
derived from the extracts of ten common herbs, appears to provide clinical improvement to
patients diagnosed with high grade prostatic intraepithelial neoplasia (HGPIN), a preneoplastic
form of PrC (8). In addition, Zyflamend® has been shown to reduce proliferation in a variety of
PrC cell lines by modulating genes that impact the cell cycle and apoptosis (9-11) at
concentrations believed to be physiologically relevant where the individual herbs had no effect
(Huang 2010).

Using castrate-resistant CWR22Rv1 cells we have demonstrated that Zyflamend®
inhibits cell growth using physiologically relevant concentrations and these effects can be
attributed to reductions in androgen receptor expression and increases in the cell cycle inhibitor
p21 as regulated by histone acetylation (Huang 2010). However, no studies have used this
experimental model (in vivo) to test the impact of bioactive herbals as the disease progresses
from androgen-dependent to androgen-independent tumor growth. As such, this study will
investigate the effects of Zyflamend® on androgen-dependent and castrate-resistant tumor
growth in vivo and determine if there is preclinical value when used in conjunction with hormone
ablation therapy at oral doses considered to be relevant to humans.
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One of the animal models to study the natural responses of prostate cancer cells to
hormone deprivation is the use of CWR22 PrC cells, derived from a primary tumor, which was
established by Pretlow‟s group in 1993. CWR22 PrC cells are highly androgen dependent and
cells regress after androgen removal and then relapse to transform an androgen-independent line,
CWR22R. Relapse of tumor is in 30-50% of the animals within 3-10 months of castration (3).
CW22RRv1 cells are castrate-resistant cells derived from relapsed CWR22 cells. CWR22Rv1
cells can survive in the absence of androgen but still response to androgen due to their isoforms
of androgen recpetors (4) while these two isoforms don‟t exist in parental CWR22 cells. CWR22
cell line and its derivative, CWR22Rv1 cells, serve a good model to study the progression of
prostate cancer to refractory.

Currently, the use of medicinal herbs and their bioactive compounds have been shown to
have the beneficial effects on reducing prostate cancer progression and incidence. A combination
of medicinal herbs is believed to have synergistic anticancer effects. In a CWR22Rv1 athymic
nude mouse model, green tea polyphenols (GTPs) and EGCG postponed the tumor by 100% (54
days) and 33% (36 days) versus control (26 days), indicating the use of combination of
phytochemicals inhibited prostate cancer cell growth, synergistically (12). These results showed
that green tea polyphenols is more effective than single green tea bioactive compound, EGCG.
Further, Zyflamend®, a polyherbal preparation derived from the extracts of ten common herbs,
appears to provide clinical improvement to patients diagnosed with high grade prostatic
intraepithelial neoplasia (HGPIN), a preneoplastic form of the disease (8). In addition,
Zyflamend® has been shown to reduce proliferation in a variety of PrC cell lines by modulating
genes that impact the cell cycle and apoptosis (9-11). To understand the effects of Zyflamend®
on the progression of prostate cancer to refractory, CWR22 cells and CWR22Rv1 cells were
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used and represented the different stages following hormone ablation therapy.

4.2

Materials and Methods
4.2.1 Supplement
Zyflamend® (New Chapter, Inc., Brattleboro, VT) is a combination of the extracts of

ten herbs commonly used in food preparations (ginger, rosemary, turmeric, Chinese goldthread,
holy basil, hu zhang, barberry, oregano, green tea and basil skullcap) (Table 4.1) (10) .
4.2.2 Cell lines
Human prostate cancer cell line, CWR22Rv1, was purchased from American Type
Culture Collection (Rockville, MD). CWR22Rv1 cells are a castrate-resistant cell line that were
maintained in RPMI 1640 media supplemented with 10% fetal bovine serum under an
atmosphere of 5% CO2 at 37oC. CWR22 cells (originally provided by Dr. Thomas Pretlow, Case
Western Reserve University, Cleveland, OH) are an androgen-dependent human prostate cancer
cell line that is propagated through donor mice (serial transplanted tumors) that are sensitive to
androgen withdrawal, and thus, share greater similarity with primary prostatic tumors than
immortalized cell lines (3).

163

Table 4.1 Compositions of individual herbal extract in Zyflamend®

Compounds

1

Percentage (%)1

Ginger

12.8

Rosemary

19.2

Turmeric

14.1

Chinese Goldthread

5.1

Holy Basil

12.8

Hu Zhang

10.2

Barberry

5.1

Oregano

5.1

Green Tea

12.8

Basil Skullcap

2.5

Total

99.7

See reference 10
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4.2.3 Animals
Five-week old castrated athymic male (nu/nu) nude mice (Harlan Sprague Dawley, Inc.,
Indianapolis, IN) were housed in wired cages with free access to water and fresh food and in a
temperature-controlled room with 14 h periods of light and 10 h periods of darkness. The health
of the animals was monitored daily. All animal manipulations were approved by the University
of Tennessee Institutional Animal Care and Use Committee and were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals (1996, NRC).

4.2.4 Diets
The background diets used in this study were based on the composition of a typical
Western diet with the following energy distribution: carbohydrate at 50%, fat at 34%, and protein
at 16%. These diets were based on a modified version of the US17 diet (Research Diets, New
Brunswick, NJ; diet # D05010801). The lipid composition was also designed to mimic that of the
Western diet, ~15% monounsaturated fats, ~13% saturated fats and 6-7% polyunsaturated fatty
acids (PUFA) where the PUFA distribution included 6% linoleic acid (LA), 0.7% alpha-linolenic
acid (ALA), 0.09% long chain n-3 PUFA (eicosapentaenoic acid, EPA, plus docosahexaenoic
acid, DHA), and 0.09% arachidonic acid (AA). The human equivalent doses of these PUFA for
the murine diets were derived from human daily intakes of 15 g, 1.33 g, 200 mg and 200 mg for
LA, ALA, EPA+DHA and AA, respectively, as shown in table 4.2. Human equivalent dose of
Zyflamend®, which is ~2 one-gram capsules/d (13) or 0.32 % (g/100 g mouse diet), was used in
the diet to maximize our ability to translate the results. When extrapolated based on differences
in metabolic activity, the level of Zyflamend® is equivalent to a daily dose of 16 mg/day/mouse.
We chose extrapolations using metabolic activity based on data evaluating interspecies
comparisons with non-energy producing nutrients (14). Prior to all dietary experiments, the
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animals were placed on the background diet for one week prior to being placed on background
diets ±Zyflamend®.

166

Table 4.2 The dietary compositions in control diet and in Zyflamend® diet
Compositions

Control
gm
kcal
17.4
15.8
54.7
49.7
16.8
34.4
100
4.4

Protein
CHO
Fat
Total
kcal/gm
Ingredient
Casien
L-Cystine
Corn starch
Maltodextin 10
Sucrose
Cellulose
Cocoa butter, deodorized
Linseed oil, RBD
Paml oil, bleached, deorderized
Safflower oil
Sunflower oil
Olive oil
Zyflamend (dry weight)
ARASCO (0.04g AA/ g)
DHASCO (0.04g DHA/ g)
Alpha linolenic acid, estyl ester
Oleic acid, estyl ester
t-BHQ
Mineral mix S10026
Calcium phoshate, dibasic
Calcium carboate
Potassium citrate
Vitamin mix V13401
Choline bitartrate
Alpha Vitamin E acetate
Total

150
3
295
75
100
50
33
3.95
42
23
21.6
0.79
0
8.75
8.75
0
5.9
0.03
10
13
5.5
16.5
10
2
0.13
877.9

Total amount
Total saturated fatty acid (SFA)
Total monounsaturated fatty acid (MUFA)
Total polyunsaturated fatty acid (PUFA)
Total n-6 PUFA
Total n-3PUFA
Ratio PUFA/SFA
Ratio PUFA/MUFA
Ratio n-6 PUFA/ n-3 PUFA

100
37.9
41.4
20.7
18.6
2.1
0.6
0.5
8.9
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Zyflamend®
gm
kcal
17.4
15.8
54.7
49.7
16.8
34.4
100
4.4

600
150
12
3
1180
295
300
75
400
100
0
50
297
33
35.55
3.95
378
42
207
23
194.4
21.6
7.11
0.79
0
0.53
78.75
8.75
78.75
8.75
0
0
53.1
5.9
0
0.03
0
10
0
13
0
5.5
0
16.5
40
10
0
2
0
0.13
3861.66
877.9
Fatty Acids (%) mole
100
37.7
41.4
20.9
18.8
2.1
0.6
0.5
8.8

600
12
1180
300
400
0
297
35.55
378
207
194.4
7.11
0
78.75
78.75
0
53.1
0
0
0
0
0
40
0
0
3861.66

4.2.5 Fatty acid analysis for diets
Fatty acid analysis of the diets was performed as described previously (15) with the
following modifications. Samples of powdered diets (100 mg), suspended in 0.9% saline with an
internal control (1, 2-diheptadecanoyl-sn-glycerol-3-phosphorylcholine (Matreya LLC, Pleasant
Gap, PA), were extracted with chloroform/methanol (1:2 v/v) followed by extraction (x2) with
chloroform. Lipids were saponified with 0.5N NaOH/MeOH at 86C for 15 minutes, followed
by trans-methylation with BF3 in MEOH (Thermo Fisher Scientific, Morris Plains, NJ) at 86C
for 10 minutes. The preparation was neutralized with 0.7 N HCl in MeOH followed by the
addition of saline. The fatty acid methyl esters were extracted with hexane and measured using a
Hewlett Packard HP 5890 Series II Gas Chromatograph (Agilent Technologies, Inc. Santa Clara
CA) with flame ionization detector and a DB23 fused silica capillary column (0.25 mm i.d. x
0.25 µm film; J&W Scientific, Folsom, CA), with hydrogen as the carrier gas. Fatty acids were
identified when compared to standards (NuChek Prep, Elysian, MN).

4.2.6 Design of Xenograft Experiments
4.2.6.1 Androgen-dependent CWR22Rv1 tumor growth
CWR22 prostate cancer cells were grown in donor mice (five-week old castrated athymic
male (nu/nu) nude mice) prior to transplantation into the experimental mice. Following growth of
xenograft tumors, the tissues were homogenized with BD Matrigel™ Basement Membrane
Matrix (BD Biosciences, San Jose, CA) and subcutaneously inoculated into the right flank of the
animals while a sustained-release testosterone pellet was implanted subcutaneously. One week
after transplantation the animals were divided into two dietary groups, ±Zyflamend
supplementation (10 mice/ group) and the growth of the tumors were monitored over the next 16
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days (Figure 4.2A). Food intake, body weights, tumor size and wet weight, and serum PSA levels
were measured at the end of the experiment.

4.2.6.2 Androgen-dependent CWR22 tumor growth following hormone deprivation
CWR22 prostate cancer cells were maintained in ten donor mice (five-week old castrated
athymic male (nu/nu) nude mice) prior to transplantation into sixty experimental mice as
described above. Sixty mice involved in the experiment were randomly divided into two groups,
30 for the control group and 30 for the Zyflamend® group. Tumors were allowed to grow in the
presence of a slow-releasing testosterone pellet. When the tumors reached a size of 1.0 cm in
diameter, the testosterone pellet was removed and mice were put on their respective diets (30
mice/group; two dietary groups, ±Zyflamend®) as shown in figure 4.2B. Additional identical
experiment was repeated and ten animals were used in each group. This experiment was
terminated at day 4 following testosterone pellet removal and xenograft tissues and blood
samples were collected for analysis. The composition of the diets is described in Table 4.2.
Regression of the tumors was monitored following the removal of testosterone after the animals
were placed on diet. Food intake, body weights, tumor size and serum PSA levels were measured.

4.2.6.3 Castrate-resistant CWR22Rv1 tumor growth:
CWR22Rv1 cells (1 × 106) were suspended in serum-free RPMI 1640 medium mixed
with BD Matrigel™ Basement Membrane Matrix (BD Biosciences, San Jose, CA) at a ratio of
1:1 (v/v) and subcutaneously inoculated into the right flank of the animals. After tumor cells
were injected, the animals were maintained on the background diet for 8 days to avoid dietary
interference with initial tumor growth and cell survival, where upon 30 animals were randomly
divided into two groups, 15 mice/group, ±Zyflamend®, for 12 days (Figure 4.2C).
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Measurements of tumor size were initiated at day 0 and monitored every other day. Tumor
volume was calculated using a formula of [0.5×length×width2] (16). Food intake and body
weights were measured every day. Serum PSA levels and tumor wet weights were measured at
the end of the study. Tumors did not grow in two animals in the control group and one animal in
the Zyflamend® group, and thus, were excluded from the study.
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A

B

C

Figure 4.2 Dietary designs on androgen-dependent CWR22 xenograft model and castrateresistant CWR22Rv1 xenograft model. A. CWR22 prostate cancer cells and testosterone pellets
were transplanted into the athymic male (nu/nu) nude mice prior to switch to the experimental
diet. Following transplantation (1 week), twenty mice were randomly placed into two groups
(n=10/group), as indicated as day 0, and the study was terminated at day 16 when the length of
tumors were between1.0 -1.5 cm. B. Dietary design using an androgen-dependent CWR22
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xenograft model following testosterone pellets removal. CWR22 prostate cancer cells and
testosterone pellets were transplanted into the athymic male (nu/nu) nude mice prior and the
tumors were allowed to grow to a length of 1.0- 1.5 cm. The mice were then randomly placed
into two dietary groups (n=30 /group), ±Zyflamend®. Additional identical experiment was
repeated and ten animals were used in each group. This experiment was terminated at day 4. C.
Dietary design using a castrate-resistant CWR22Rv1 xenograft model. CWR22Rv1 prostate
cancer cells were transplanted into the athymic male (nu/nu) nude mice. After 8 days, the mice
were randomly placed into two dietary groups ±Zyflamend® (n=10 /group). The study was
terminated at day 12. .

172

4.2.7 RNA isolation and quantitative RT-PCR

Total RNA was isolated from CWR22 xenograft tissues using Trizol reagent (Invitrogen,
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100%
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water.
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc.
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™
(Thermo Scientifc Wilmington, DE). Total RNA (2 μg) from each sample was mixed with
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System,
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR
amplification with primer sets (2.5 μM) of androgen receptor sense, 5‟CCTGGCTTCCGCAACTTACAC-3‟ and antisense 5‟- GGACTTGTGCATGCGGTACTCA-3‟,
and prostatic specific antigen sense, 5‟ - ACCAGAGGAGTTCTTGACCCCAAA-3‟ and
antisense 5‟- CCCCAGAATCACCCGAGCAG-3‟ were examined. Amplification was performed
using a standard thermocycle program beginning with an initial temperature at 94°C for 1 min
followed by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was
examined in triplicate and the amounts of PCR product were normalized with 36B4, 5‟TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as
the internal control.
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4.2.8 Western blotting
Xenograft tissues (20 mg) were lysed in the presence of cell lysis buffer (Cell Signaling
Technology®, Inc. Danver, MA). Protein content of the lysates were quantified by BCA protein
assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (20 ug) were fractioned by 8~12%
SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by electroblotting.
The membranes were blocked using 5% nonfat dry milk in 0.1% tris buffered saline-Tween-20
(TBST) for 1 hour and were incubated in TBST containing primary antibodies overnight at 4°C.
The membrane was incubated with anti-mouse or anti-rabbit secondary antibody conjugated with
horseradish peroxidase (HRP) (Cell Signaling Technology®, Inc. Danver, MA). Protein
expression was detected with a Pierce ECL Western Blotting detection system. Each membrane
was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ). Antibodies of AR, phosphorAKT, AKT (Cell Signaling Technology®, Inc. Danver, MA), IGF-1R and COX2 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) were used. β-actin (with anti-β-actin antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA)) was used as the control.

4.2.9 Serum PSA measurement
Serum PSA levels were measured using PSA ELISA kit (MP Biomedicals, Solon, OH) as
per manufacturer‟s instructions. Briefly, blood was harvested and serum was isolated by
centrifugation (13,000 x g at 4 °C for 20 min). PSA concentration was calculated based on
readings at 450 nm using a SpectraCount microplate photometer (PerkinElmer Inc, Waltham,
MA).
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4.2.10 Statistic analysis
The results are presented as mean ± SEM and are analyzed by a two-way ANOVA when
multiple comparisons were made. Differences were considered significant at p<0.05.

4.3

Result
4.3.1 Effects of hormone ablation on select biomarkers
The impact of hormone deprivation on select biomarkers of PrC was compared in a

xenograph model using CWR22-derived tumors prior to and after the removal of a testosterone
pellet in castrated athymic nude mice. Following testosterone removal, protein levels of
androgen receptor, pAKT (the activated form of AKT), insulin-like growth factor -1 receptor
(IGF-1R) and cyclooxygenase-2 (COX-2) were reduced by 85%, 60%, 46% and 49%,
respectively (Figure 4.3 and Figure 4.4).
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A

B

Figure 4.3 Protein expression of androgen receptor (AR) and phospho- AKT (pAKT) in CWR22derived tumors prior to and after hormone deprivation. Bars are mean±SEM. HAT: hormone
ablation therapy.
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normalized protein level by b-actin
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Figure 4.4 IGF-1R and COX2 expression (protein) from CWR22-derived tumors from mice on
Control and Zyflamend®-supplemented diets prior to and after hormone deprivation. Bars are
mean±SEM.
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4.3.2 Effects of Zyflamend® on the growth of CWR22 xenograft tumors

CWR22 cells were transplanted into the flank of athymic nude mice in the presence of
testosterone (a slow-releasing pellet inserted subcutaneously) and tumor growth was monitored
in mice fed diets devoid of or containing Zyflamend®. After 16 days on diet, tumor size was
significantly smaller (>50%) in those animals consuming Zyflamend® (Figure 4.5). There were
no differences in body weights and food intake (Table 4.3). Circulating PSA levels were
positively correlated with tumor size, where reductions (~40%) in tumor weight (wet weight) and
PSA levels (ng/ml) mimicked the reductions (~50%) in tumor size. Expression of PSA mRNA
was significantly reduced in tumors from mice fed Zyflamend® compared to mice fed the
control diet; however, androgen receptor expression (protein and mRNA) was unaffected by diet
(data not shown).
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Table 4.3 Tumor sizes and biological indices from CWR22-derived tumors from mice on the
Control and Zyflamend®-supplemented diets.
Zyflamend®
Control diet

p-value
diet

Relative tumor size (100%)

4.08±0.82

2.03±0.35

0.042

Tumor wet weight (g)

0.25±0.05

0.153±0.03

0.132

Food intake (g/d)

4.79±0.08

4.96±0.06

0.324

Body weight (g)

33.3±0.88

35.24±01.11

0.967

90.69±17.27

55.76±18.34

0.186

PSA (ng/ml)

Values are means±SEM.
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Figure 4.5 Tumor growth of CWR22cells inserted into the flank of nude (nu/nu) mice. The tumor
size was measured and calculated using a formula of 0.5×length×width2 and presented as a ratio
of tumor size normalized to initial tumor size. Values are mean±SEM, n=10/group.
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4.3.3 Effects of Zyflamend® on the growth of CWR22 xenograft tumors following
hormone ablation

CWR22 cells were transplanted into the flank of athymic nude mice in the presence of
testosterone and allowed to grow. When the tumors reached the appropriate diameter (1.0-1.5 cm)
the testosterone pellet was removed, the animals were placed on their respective diets
(±Zyflamend®) and tumor regression was monitored. Figure 4.6A represents the change in
tumor size for each animal in each group following hormone deprivation. Within the first 4 days,
tumors appeared to continue to grow in the control-fed animals prior to regression (Figure 4.6C),
while tumor size in the Zyflamend®-fed group was reduced, after which time, tumor size
continued to decline in both groups where Zyflamend® had a significantly greater effect
compared to controls (within the first 20 days). The variability of response to hormone ablation
was significantly smaller with Zyflamend® (Figure 4.6B). The length of time to reduce tumor
size by an average of 50% in the Zyflamend® and control groups was 11days and 19 days,
respectively (p<0.05) (Figure 4.6C). In addition, PSA levels (ng/ml) were correlated with tumor
size (Figure 4.6D) and this was reflected in a reduction of PSA mRNA expression, but the
changes in mRNA and protein levels of androgen receptor were not significant (Figure 4.7).
Expression of IGF-1R was reduced post- versus pre-hormone ablation (Figure 4.4), but
Zyflamend did not reduce IGF-1R expression further (Figure 4.4). Histone deacetylase 5 (HDAC
5) expression (mRNA) was lower in the Zyflamend® group compared to expression in tumors
from the control group (Fig. 7). Food intake among dietary groups were not different (Table 4.4),
but the animals in the Zyflamend® group lost less weight compared to those on the control diet
(p<0.05) following hormone ablation.
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Figure 4.6 The impact of hormone deprivation on CWR22-derived tumors from mice on Control
or Zyflamend®-supplemented diets. A. Relative tumor sizes in each individual animal over 100
days. B. Mean variances of relative tumor size for each dietary group over 100 days.. C. Changes
in mean tumor volume for the first 20 days following hormone deprivation (mean±SEM). D.
Mean serum PSA levels versus tumor sizes for each dietary group at day 4 after testosterone
removal.
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Figure 4.6 Continued.
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Figure 4.7 Expression of androgen receptor (AR) and PSA from CWR22-derived tumors from
mice on diets from mice on Control or Zyflamend®-supplemented diets at day 4 following
hormone deprivation. A. AR and PSA RNA expression levels of xenograft tissues were detected
(n=12, mean±SEM). B. AR protein analysis of xenograft tissues were detected (mean±SEM,
n=4-5/group).
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Figure 4.8 mRNA expression of class I and II histone deacetylases (HDACs) from CWR22derived tumors from mice on diets from mice on Control or Zyflamend®-supplemented diets at
day 4 following hormone deprivation. (bars are mean±SEM, n=5)
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Table 4.4 Tumor sizes and biological indices from CWR22-derived tumors at day 4 compared to
day 0 following testosterone pellets removal in mice fed Control or Zyflamend®-containing diets.

Control diet

Zyflamend® diet

p-value

1.27±0.09

0.50±0.04

<0.001

Food intake (g/d)

6.0±0.46

6.1±0.44

0.638

Weight change (g)

-1.0±0.13

-0.5±0.15

0.001

81.0±11.16

58.8±8.12

0.187

Relative tumor size compared to day 0
(100%)*

PSA (ng/ml)

*Data was pooled from two individual experiments. Values are means±SEM.
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4.3.4 Effect of Zyflamend® on androgen-independent growth of CWR22Rv1
xenograft tumor

Castrate-resistant CWR22Rv1 cells were transplanted into the flank of castrated athymic
nude mice (in the absence of testosterone). After 8 days, the mice were switched to diets devoid
of or containing Zyflamend® and tumor growth was monitored. After 12 days on their respective
diets, tumor size was significantly smaller (46%) in those animals consuming Zyflamend® as
tumor growth began to diverge within the first 2 days on the experimental diets (Figure 7.9A).
Food intake and weight gain were not significantly different among dietary groups (Table 4.5).
PSA levels (ng/ml) were low and could not be detected in 13/14 animals on the Zyflamend® diet,
while almost half of the control animals (6/13) had measurable amounts of PSA (Table 4.5).
Androgen receptor expression (protein) was significantly reduced in the xenograph tumors from
mice fed Zyflamend® compared to tumors from mice fed the control diet (Figure 7.9B). HDAC
4 expression (protein) was lower in Zyflamend®-treated tumors compared to tumors from the
control group (Figure 7.9C).
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Figure 4.9 Growth of CWR22Rv1-derived tumors from mice on Control or Zyflamend®supplemented diets. A. Tumor size was calculated using the formula 0.5×length×width2. B.
Androgen receptor expression (protein) in CWR22Rv1-derived tumors. C. Expression (protein)
of histone deacetylases 1 and 4 (HDAC 1 & 4) from CWR22Rv1-derived tumors from mice on
Control or Zyflamend®-supplemented diets.
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Table 4.5 Tumor sizes and biological indices from CWR22Rv1-derived tumors from mice on the
Control and Zyflamend®-supplemented diets.

Control

Zyflamend®

diet

diet

13

14

Tumor size (cm3)

0.24±0.04

0.13±0.03

0.033

Tumor wet weight (g)

0.18±0.02

0.12±0.03

0.074

Food intake (g/d)

2.95±0.05

3.10±0.03

0.098

Final body weight (g)

25.31±0.37

25.19±0.49

0.609

Weight gain (g)

2.28±0.19

2.91±0.27

0.062

6/13*

1/14*

Animal number

PSA (ng/ml)

p-value

*Number of detectable plasma PSA level in the group. Values are means±SEM.
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4.4 Discussion

There are only a few preclinical experimental models of PrC and most of those do not
address the progression of metastatic PrC. This paper reaffirms the proof of concept that
metastatic PrC can be divided into four phases, where each phase may respond differently to
therapeutic intervention with unique regulatory mechanisms (5). Furthermore, we propose that a
mouse model of metastatic PrC may provide a unique opportunity to study the impact of diet as
an adjuvant to standard therapies, in this case, hormone ablation.

Metastatic PrC travels to lung, liver and primarily bone. Following diagnosis, hormone
deprivation therapy is commonly prescribed because prostate epithelial cells are dependent upon
androgens for growth. This therapy results in tumor regression and stabilization for several years,
after which time the residual cells appear to become refractory, resulting in castrate-resistant
regrowth. Unfortunately, this relapse is invariably fatal within two years with few therapeutic
strategies.

The experimental model used in this study follows a similar pattern. CWR22 cells are an
androgen-dependent human prostate tumor cell line that mimics this process (3). When inserted
subcutaneously in athymic nude mice, these cells grow into a solid tumor, and following
androgen withdrawal the tumors shrink. However, relapse can occur within a year in the absence
of androgens and the cells from the relapsed tumor, CWR22R, are classified as castrate resistant.
An immortalized cell line derived from these relapsed cells, CWR22Rv1 cells, has been used as
a model of castrate-resistant PrC because they produce human PSA, contain an active androgen
receptor and can grow in the absence of androgens (17). This study explores the impact of diet in
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a model of metastatic PrC in the presence or absence of testosterone and is an extension of our
previous work with this cell model in vitro and dietary intervention on metastatic PrC (5).

Zyflamend® is derived from the extracts of ten different herbs and each has been
reported to have medicinal properties in vitro (18-19, 7) and therapeutic value in humans.
Individuals diagnosed with HGPIN are at increased risk for developing PrC (20). When this
polyherbal preparation was used in a Phase I clinical trial with patients diagnosed with HGPIN,
reductions in PSA and re-diagnosis to benign forms of prostate tissue were reported in 60% of
the participants (8, 13). Based on this data, we investigated the effects of Zyflamend® in our
model of castrate-resistant PrC. The oral dose of Zyflamend® for these in vivo studies was
calculated to be ~600 mg/kg body weight (0.32% of diet, w/w). Allometric scaling for a human
dose was based on the equivalent of ~two 1 g soft gel capsules of Zyflamend per day (based on
energy for allometric scaling between species) (14). To give an idea how this dose may relate to
individual doses of phytochemicals typically used, if one were to estimate the levels of
curcumoids from Zyflamend®, it would be equivalent to ~2 mg/kg body weight per mouse per
day (Zyflamend® contains ~0.35% curcumoids, w/w). These levels are well below typical levels
of curcumin supplemented to the diets of rodents (200-1000 mg/kg body weight) (19). We used
these conservative values in an effort to provide human relevance to our data.

We investigated the effects of Zyflamend® on androgen-dependent and castrate-resistant
PrC tumor growth and explored its interaction with androgen deprivation. We focused our
attention on several key biomarkers that have been related to metastatic PrC, vis, PSA and
androgen receptor.
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CWR22 cells represent those androgen-dependent metastatic tumor cells at the initial
phase of tumor growth prior to hormone ablation treatment. Zyflamend® significantly inhibited
tumor growth. This was somewhat surprising because dietary long chain n-3 polyunsaturated
fatty acids (i.e., eicosapentaenoic acid, EPA), which are noted to be antitumorigenic, had no
significant effect in this model at this phase of the disease process (5). We and others have
shown that Zyflamend® inhibits growth of other androgen-dependent PrC cells in vitro (i.e.,
LNCaP cells) at doses considered physiologically relevant (review earlier chapters of this
dissertation) (9). These previous effects were related to increases in biomarkers of apoptosis
(caspase-3 activity and PARP cleavage) along with increased expression of the cell cycle
inhibitor p21 (9). While we did not look at p21 expression in these tumors, we previously
reported that Zyflamend® robustly increases p21 expression via epigenetic regulation in
CWR22Rv1 cells.

Of interest is the ability to use diet to potentiate the impact of standard therapies, in this
case, hormone derivation. The use of Zyflamend® in conjunction with the removal of
testosterone potentiated tumor regression where the time needed to reduce tumor size was almost
cut in half (11 days versus 19 days) and the response of the tumors to intervention was more
immediate with Zyflamend® and less variable. The reduction in tumor size correlated with
circulating PSA levels, an important biomarker for prostate epithelial cells and tumor growth.
Although androgen receptor expression (mRNA) declined following hormone deprivation, we
did not observe a significant reduction with dietary Zyflamend®, but PSA expression in those
tumors was significantly reduced. The lack of a significant effect on androgen receptor
expression with Zyflamend post-HAT could be due the fact that androgen receptor expression
was down-regulated by 85% pre- to post-hormone ablation (in the absence of Zyflamend®).
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Furthermore, pAKT expression, a reported regulator of androgen activation (21) was also
significantly down-regulated (by ~60%) when testosterone was removed (independent of
Zyflamend®).

This data and the data previously published with dietary EPA (5) are the first evidence to
suggest that diet could be used in conjunction with hormone ablation to potentiate its effects.
This could have an impact on potentially extending the subsequent latency phase prior to relapse,
a key objective for increased survival (5). In humans, the latency period associated with hormone
ablation therapy lasts approximately two years (22). Refractory growth is typically treated with
chemotherapy in an effort to prolong survival by several months. It has been suggested that
reactivation of androgen receptor in the absence of androgens may be one of the underlying
mechanisms associated with this relapse (23).

Zyflamend® inhibited growth of CWR22Rv1-derived tumors by 46% within 12 days on
diet. These cells represent a model of castrate-resistant tumor relapse. These results are
consistent with data that shows Zyflamend® inhibits the growth of CWR22Rv1 cells in vitro
(review earlier chapters of this dissertation), and with other androgen-independent PrC cells (i.e.,
PC3 cells) (11). The latter effect was associated with reductions in 12-lipoxygenase expression
and phosphorylation of the cell cycle regulator retinoblastoma protein (Rb) (11).

The effects in the current study were associated with significant reductions in androgen
receptor expression (protein). Similarly, using CWR22Rv1 cells in vitro androgen receptor
expression and nuclear localization was significantly reduced following Zyflamend® treatment,
further supporting our in vivo results. In addition to the reduction of androgen receptor, the
inhibition effects of Zyflamend® were associated with a reduction in histone deacetylase activity.
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Zyflamend® is a general HDAC inhibitor (class I and II) in CWR22Rv1 cells in vitro and here
we show that Zyflamend® inhibits HDAC expression in xenograph tumors (Fig. 4.7 and 4.8).
Inhibition of HDACs has been shown to inhibit androgen receptor and PSA expression in both
hormone sensitive and insensitive PrC cells and thus could be likely mechanisms behind our
effects (24).

In summary, we used a preclinical model of metastatic PrC by which the impact of diet
can be investigated prior to or following hormone ablation therapy. Zyflamend®, a mixture of
polyherbal extracts, inhibited androgen-dependent (CWR22 cells) and castrate-resistant tumor
growth (CWR22Rv1 cells) in vivo using levels in the diet consistent with those recommended for
humans. PSA levels correlated with tumor growth (or regression) and expression was reduced
when Zyflamend® was added to the diet in all phases of the disease. Similarly, androgen
receptor expression was inhibited following hormone deprivation and in castrate-resistant tumors,
and these effects could be mediated by down-regulation of pAKT and HDAC expression. The
mechanisms of action for Zyflamend® have been clearly elucidated in vitro (review earlier
chapters of this dissertation) and are consistent with the results presented in this study.

194

Reference
1.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA

Cancer J Clin. 2008;58:71-96.
2.

Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer:

geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171-84.
3.

Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S,

Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the
first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains
both in vivo and in soft agar. Cancer Res. 1996;56:3042-6.
4.

Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ.

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer
xenograft and cell line. Cancer Res. 2002;62:6606-14.
5.

McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N, Lih FB,

O'Rourke D, Whelan J. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation
therapy in androgen-dependent prostate cancer. Am J Pathol. 2008;173:229-41.
6.

Howells LM, Mitra A, Manson MM. Comparison of oxaliplatin- and curcumin-mediated

antiproliferative effects in colorectal cell lines. Int J Cancer. 2007;121:175-83.
7.

Moiseeva EP, Manson MM. Dietary chemopreventive phytochemicals: too little or too

much? Cancer Prev Res (Phila Pa). 2009;2:611-6.
8.

Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson MC, Stone

BA, Katz AE. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a
phase I clinical trial. J Soc Integr Oncol. 2009;7:43-51.
9.

Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Zyflamend, a unique

195

herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate
cancer cells that lack COX-2 expression. Nutr Cancer. 2005;52:202-12.
10.

Sandur SK, Ahn KS, Ichikawa H, Sethi G, Shishodia S, Newman RA, Aggarwal BB.

Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and
potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa Bregulated gene products. Nutr Cancer. 2007;57:78-87.
11.

Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend-

mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb
protein phosphorylation. Cancer Biol Ther. 2007;6:228-36.
12.

Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S, Adhami VM, Ahmad N,

Raisuddin S, Mukhtar H. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic
nude mice by green and black teas. Carcinogenesis. 2006;27:833-9.
13.

Rafailov S, Cammack S, Stone BA, Katz AE. The role of Zyflamend, an herbal anti-

inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr
Cancer Ther. 2007;6:74-6.
14.

Rucker R, Storms D. Interspecies comparisons of micronutrient requirements: metabolic

vs. absolute body size. J Nutr. 2002;132:2999-3000.
15.

Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Whelan J. Highly unsaturated (n-

3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce
tumorigenesis in Apc(Min/+) mice. J Nutr. 2000;130:2434-43.
16.

Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude)

mice. Cancer Chemother Pharmacol. 1989;24:148-54.
17.

Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS,

196

Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line,
22Rv1. In Vitro Cell Dev Biol Anim. 1999;35:403-9.
18.

Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett.

2004;215:129-40.
19.

Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, Hudson EA,

Manson MM. Predicting the physiological relevance of in vitro cancer preventive activities of
phytochemicals. Acta Pharmacol Sin. 2007;28:1274-304.
20.

Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Mechanisms of

disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in
the prostate. Nat Clin Pract Urol. 2007;4:321-32.
21.

Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the

phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets.
2007;7:591-604.
22.

Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin

Oncol. 2009;21:260-5.
23.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T.

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the
nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response
to maximal androgen blockade. Eur Urol. 1997;31:216-9.
24.

Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone

deacetylases are required for androgen receptor function in hormone-sensitive and castrateresistant prostate cancer. Cancer Res. 2009;69:958-66.

197

Summary and Conclusions
Advanced prostate cancer is aggressive and is the second leading cause of death from
cancer in males in the United State. Malignant prostate cancer cells metastasize to adjacent and
more distant tissues, such as bone. The characteristics of advanced prostate cancer can be
outlined by four phases. The cells in the first phase are androgen-sensitive. Their growth is
dependent upon the presence of androgens. Typically, the resultant tumors undergo regression
following hormone ablation/deprivation therapy (Phase II), followed by an extended remission
phase (Phase III). This remission phase usually lasts 3 to 5 years and eventually relapses (Phase
IV). The relapsed cells grow in the absence of androgens and appear to be more aggressive with
typical survival times limited to 1-2 years. Therefore, a critical barrier in treating advanced
prostate cancer is finding effective treatments for castrate-resistant forms of the disease.

In this study, CWR22 cells and relapsed CWR22 cells (in the form of CWR22Rv1 cells)
were chosen for the experiments because they represent those transitions associated with
advanced prostate cancer. CWR22 cells only grow in the athymic nude mice supplied with
testosterone and produce prostate specific antigen (PSA). After removal of testosterone, CWR22
cells regress and eventually relapse. These relapsed cells are referred to as CWR22R cells. They
are castrate resistant, but still respond to androgens and can produce PSA. Similarly, prostate
cancer cells in patients whose disease has relapsed following androgen ablation therapy express
androgen receptors and produce PSA.

The use of herbs, botanicals and their bioactive components have been shown to be
effective in many tumor cells lines in vitro and in vivo by inhibiting cell and tumor growth.
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Zyflamend®, a polyherbal preparation derived from the extracts of ten herbs, appears to provide
clinical improvement to patients diagnosed with high grade prostatic intraepithelial neoplasia
(HGPIN), a preneoplastic form of the disease. Our findings suggest that Zyflamend® reduced
cell proliferation in a variety of PrC cell lines, including RWPE-1 (representing premalignant
cells), LNCaP (androgen-dependent), PC3 (androgen-dependent) and CWR22Rv1 (castrateresistant) cells.

In the androgen-dependent phase of the disease (Phase I), Zyflamend® significantly
inhibited growth of CWR22-derived tumors. Then, Zyflamend® potentiated the effects of
hormone ablation (Phase II), reducing expression of PSA and HDAC5, important therapeutic
targets. In an effort to address the issue of castrate-resistant relapse (Phase IV), CWR22Rv1 cells
were used under in vivo conditions where mechanisms were extensively explored under in vitro
conditions. Zyflamend® significantly inhibited CWR22Rv1-derived tumor growth. In vitro
experiments demonstrated that the antitumorigenic effects of Zyflamend® were mediated, in part,
by significantly enhancing the cell cycle inhibitors p21 and p27. These effects were mediated
epigenetically via hyperacetylation of histones. Universal inhibition of histone deacetylases was
responsible for these effects and these results were, in part, recapitulated in vivo (reductions in
HDAC1 and 4 expressions).

Important to castrate-resistant relapse is the reactivation of the androgen receptor,
possibly through the upregulation of IGF-1/IGF-1R signaling, and finding therapies that can
target this process is a priority. Zyflamend® inhibited the expression of IGF-1R and IGF-1stimulated cell proliferation. Levels of androgen receptor in CWR22Rv1 cells were reduced,
including translocation to the nuclear fraction. These effects were originally believed to be
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mediated by PI3K/AKT signaling through crosstalk between IGF-1R and androgen receptor;
however, a definitive link could not be made.

The effects of Zyflamend are multifactoral and this is probably why it is so effective at
the doses used. It inhibits tumor cell proliferation as evidenced by BrdU incorporation, inhibition
of the expression of Ki67, fatty acid synthase and its upstream regulator SREBP-1c, and it
increases markers of programmed cell death (increasing caspase 3 and PARP cleavage and
reducing Bcl-2 expression). Furthermore, because epigenetic regulation of cancer is an
environmentally driven process, finding therapeutic interventions that target acetylation and
methylation processes are a priority. Zyflamend® appears to be a universal HDAC inhibitor. As
such, the results in vitro and in vivo provide a logical rationale for the use of Zyflamend® in
clinical trials because it appears to be effects at physiologically relevant concentrations, it has
multiple mechanisms, in addition to its efficacy in multiple phases of a model of advanced
prostate cancer.
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